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Medical Cannabis is receiving renewed interest in clinical practice due to the gradual
increase over the last few decades of cannabis legalization and high-quality research on the
potential benefits of cannabis for treating a variety of conditions (NASEM, 2017; Nursing Care
of the Patient, 2018). However, the pace of medical cannabis legalization and research are
outpacing the training for medical providers, leaving gaps in their confidence and ability to
safely guide patients using medical cannabis (NCSBN, 2018). Medical providers are increasingly
fielding questions from patients regarding the use of medical cannabis for conditions commonly
seen in clinical practice, but many are uncertain of if and how they should guide patients on this
use. The aim of this research is two-fold: to assess current barriers to medical providers
discussing medical cannabis with their patients; and to assess the impact a one-hour educational
presentation can have on addressing these barriers and increasing the likelihood of providers
engaging in discussions. Though the results of this research may be limited by the small sample
size surveyed, they could highlight barriers present in clinical practice and indicate possible areas
for future research in expanding cannabis education for medical providers.
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CHAPTER 1
RATIONALE
Medical cannabis is receiving renewed interest in clinical practice due to the gradual
increase in cannabis legalization and high-quality research on the potential benefits for treating a
variety of conditions (NASEM, 2017; Nursing Care of the Patient, 2018). However, the pace of
medical cannabis legalization, use, and research, is outpacing the training for medical providers
leaving gaps in their confidence and ability to safely guide patients using medical cannabis
(NCSBN, 2018).
Legalization and Use of Medical Cannabis
Despite being restricted by federal law, medical cannabis has become more prevalent in
clinical practice as individual states pass their own regulations allowing its use (Nursing Care of
the Patient, 2018). As of May 2021, medical cannabis is now legal in some form in 46 states and
four territories with 36 states legalizing it for medical use and 18 of these also legalizing for
recreational use, Maine included (State Medical Marijuana Laws, 2021). A 2019 study analyzing
data from state registrations estimated that three million Americans use medical cannabis for
relief for a variety of conditions, and this only includes those using medicinal cannabis with
formal state authorization, not those without (Americans for Safe Access, 2019).
Cannabis is also the most commonly used illicit drug with a nationwide survey in 2105
estimating that 22.2 million Americans ages 12 and older used cannabis in the past 30 days,
rising from 6.2% in 2002 to 8.6% in 2015, which is likely even higher today due to widespread
increases in legalization (Bostwick et al., 2012; NASEM, 2017; Patel & Marhawa, 2021). In
effect, millions of patients in clinical practice are using medical cannabis and providers need to
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be discussing the risks and benefits of this use with their patients as they do with any other
medicine.
Research on Medical Cannabis
High-quality clinical evidence exists and is rapidly emerging on the efficacy of medical
cannabis for treating certain patient conditions, despite the restrictions in America from being
classified as Schedule I (NASEM report, 2017; Sulak, 2021). Many other countries, including
Canada, do not have the restrictions on cannabis research and have acknowledged its medical use
and have provided much of this high-quality research (Understanding the New Access to
Cannabis for Medical Purposes Regulations, 2016). Several of the randomized clinical trials
(RCTs) studying the efficacy of medical cannabis for treating neurological conditions like
multiple sclerosis (MS), chronic pain, insomnia, and post-traumatic stress disorder (PTSD) have
been done with Nabiximols, a formulated cannabis extract with equal parts tetrahydrocannabinol
(THC) and cannabidiol (CBD) legal in the United Kingdom and Europe for the treatment of MS
and spasticity, which is currently awaiting approval in the United States as Sativex (Healthcare
Professionals [GW], n.d.; Russo et al., 2018). Other RCTs have used Epidiolex, a purified
version of plant-based CBD legal in the United Kingdom and European Union for the treatment
of severe epilepsy. In 2018, this led to recent FDA approval in the United States for the same use
(Healthcare Professionals [GW], n.d.; Russo et al., 2018).
In 2015, the World Health Organization (WHO) produced one of the most prominent
reports summarizing the clinical evidence for medical cannabis concluding that cannabis should
be removed from scheduling to allow for research. In 2020, the United Nations approved the
report (Current Scheduling Regulations [UN], 2021; Madras, 2015). The second most prominent
and comprehensive report came from the National Academies of Science, Engineering, and
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Medicine (NASEM), which charged a committee with doing a rigorous review of the scientific
research published from 1999 to 2017 about the health impacts of cannabis and cannabinoids and
their therapeutic effects and risks for harm. The committee considered more than 10,000 highquality studies to reach its nearly 100 conclusions, determining that 86% of the conditions
patients use medical cannabis for are supported by strong evidence and that scheduling of
cannabis should be reviewed to allow for more rigorous and quality research (NASEM, 2017;
Rapaport, 2017).
Support from Medical Community
Even before the WHO and NASEM reports concluded there was strong clinical evidence
to support the use of medical cannabis, most medical providers already supported its use. A 2013
poll in the New England Journal of Medicine found that more than 75% of US physicians think
medical cannabis is a safe and effective treatment (Adler, 2013). The American Medical
Association (AMA), the American College of Physicians (ACP), and the American Academy of
Pediatrics (AAP) have all released statements of support calling for cannabis scheduling to be
reviewed to allow for research, with some medical associations like the ACP and AAP openly
acknowledging the evidence for medical use and requesting more clinical trials and
pharmaceutical development (NORML, 2015). However, this support from the medical
community has not translated to increased training on medical cannabis for providers.
Lack of Training for Medical Providers
Many providers do not realize the distinction between medical use and recreational use,
where the goal of medical cannabis is not impairment but to improve health and function using
measured doses and controlled ratios of THC:CBD with much less risk of impairment or abuse
than recreational use (Cerdá, 2020; Williams et al., 2017). Some medical programs like the
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National Council of State Boards of Nursing have recently updated their guidelines requiring that
medical cannabis education be included in curriculum to provide nurses with “principles of safe
and knowledgeable practice to promote patient safety when caring for patients using medical
[cannabis]” (NCSBN, 2018; Nursing Care of the Patient, 2018). However, the requirement for
medical cannabis education is not the case for all medical curricula and, even when it is required,
has not often transferred to actual practice. A 2018 national survey of US medical school
curriculum deans, Washington University fellows and residents, and Association of American
Medical Colleges Curriculum Inventory database found 67% of the deans and 90% of the
residents reported graduates were “not at all prepared” to recommend medical cannabis, while
85% reported “receiving no formal education” (Evanoff et al., 2018).
This lack of medical training on cannabis may be a significant barrier to providers
discussing the use of medical cannabis with their patients using it or those wanting to use it. A
survey of a large comprehensive cancer center in Seattle found that although 21% of the patients
were using cannabis to treat their symptoms from chemotherapy, 74% surveyed wanted more
information and guidance on cannabis from their health care team, yet only 15% reported they
received it (Pergram et al., 2017). This survey reveals there may be many patients wanting to
discuss medical cannabis with their providers, but unfortunately the providers are not doing this.
A 2018 survey of medical oncologists in Minnesota set out to assess the possible barriers
that may be preventing providers from discussing and recommending medical cannabis with
their patients. There were 14 questions designed to identify the providers’ current practices
regarding medical cannabis, as well as their knowledge and attitude towards it. Overall, the
study revealed great support among providers for exploring medical cannabis with their patients,
however, very few oncologists reported they had formal training on cannabis, with 36%

4

reporting they were “not or not at all confident” discussing the risks and benefits, and 85%
reporting they wanted more education on cannabis (Zylla et al., 2018). Other perceived barriers
were, in order of greatest to smallest barriers: concerns about cost, inadequate research,
pros/cons of use, FDA approval, risk of abuse/misuse, quality of product, legality for prescriber
and patient, social stigma, and the health group not allowing or supporting discussion of medical
cannabis (Zylla et al., 2018). Though this survey represents a specialized segment of the medical
field, it reveals that lack of education on these topics may be a significant barrier to providers
discussing medical cannabis with patients and suggests that providing them with the necessary
education may help bridge this gap.
Impact on Patients Using Medical Cannabis
Many medical providers are increasingly fielding questions from patients using cannabis
for a multitude of conditions commonly seen in clinical practice, such as chronic pain, insomnia,
neuropathies, anxiety, arthritis, nausea/vomiting, irritable bowel syndrome (IBS), opioid
reduction, etc. and are uncertain how to answer these questions (Nursing Care of the Patient,
2018). With Maine’s recent legalization of cannabis for recreational use in adults, questions
about medical cannabis are expected to likely increase.
Many patients are using medical cannabis and in need of guidance from their providers.
However, most providers lack the education and confidence to be able to discuss the
risks/benefits of cannabis and guide their patients. This leaves millions of patients on their own
experimenting trying to determine the right type of cannabis, dose, method of administration,
frequency, and duration, to find relief for their suffering and various conditions.
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Goal of Research: Assess Barriers and Impact of Intervention
The goal of this thesis therefore is two-fold: one, to assess current barriers in clinical
practice to medical providers discussing and guiding medical cannabis use with their patients;
and two, to explore the impact a brief educational intervention can have on addressing these
barriers and increasing the likelihood of providers engaging in these discussions. Though the
results of this study may be limited by the small sample size surveyed and the limited duration of
the educational training, it could highlight barriers present in general clinical practice and
indicate possible areas for future research in expanding cannabis education for all medical
providers.
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CHAPTER 2
BACKGROUND OF MEDICAL CANNABIS USE
The use of cannabis for medical purposes has deep roots dating back over 5,000 years
with the earliest written reference in 1500 BC in the Chinese Pharmacopeia then spreading to
Egypt, India, Africa, and by the 1850’s into the Western world and listed in the US
Pharmacopeia as a tincture for numerous afflictions including neuralgia, cholera, dysentery,
alcoholism, opiate addiction, incontinence, convulsions, insanity, menstrual bleeding, insomnia,
anorexia, dyspepsia, etc., (Bostwick, 2012; Ryan et al., 2021; The Report from the National
Commission, 1972). A comprehensive review of the use of medical cannabis in America shows
it held “a prominent position in the history of medicine, recommended by many eminent
physicians for numerous diseases” noted particularly for its analgesic, anticonvulsive, anxiolytic,
and antiemetic properties, was commonly sold over the counter, and was the 3rd-4th most
common ingredient in drug preparations, but through the decades moved from “a legal and
frequently prescribed status to illegal, driven by political and social factors rather than science”
(Baron, 2015; Bearman et al., 2018).
There are many books and documentaries documenting these factors as well as the racism
behind the campaign in the 1930’s to criminalize cannabis stemming from an anti-minority
sentiment growing in the southern and western states where there was an influx of immigrants
from Mexico and “Negro” jazz musicians who commonly used cannabis (Earleywine, 2005;
Ryan et al., 2021; Weed the People, 2018). The head of the newly formed Federal Bureau of
Narcotics, Henry Aslinger, stoked racist fears citing false instances of minorities committing
crimes on cannabis saying “marijuana is the evil Mexican plant that drives you insane,” “makes
darkies think they’re as good as white men,” and “causes white women to seek sexual relations
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with Negroes” though he admitted in private memos that these accusations were all fabricated
(Earleywine, 2005; Wing, 2014). Aslinger’s campaign was propagated by William Hearst who
owned most of the newspapers at the time and had major investments in the timber and paper
industry which feared competition from hemp that required 75% less chemicals to make paper
than wood pulp (Bearman, 2017; Earleywine, 2005; Wing, 2014).
The campaign to criminalize cannabis was successful and led to the passage of the “The
Marijuana Tax Act” in 1937 which required anyone using the plant to register and pay a tax or
risk $2,000 fine or 5 years imprisonment (Zuardi, 2006). The American Medical Association
opposed this act explaining that there was currently no drug available to replace cannabis for
many of the conditions it was used to treat. Science was ignored, and cannabis was no longer
sold over the counter and was removed from the pharmacopeia soon after in 1941 (Baron, 2015;
NCSBN, 2018; The Report from the National Commission, 1972).
In 1970, The Controlled Substances Act (CSA) was passed, placing cannabis temporarily
in the list of Schedule I Controlled Substances with “high potential for abuse” and “no medical
use” pending a commission’s investigation. (Controlled Substances Act [CSA], 1970). In 1972,
the commission appointed by President Nixon, known as the Shafer Commission, thoroughly
reviewed the research and released its report two years later “Marijuana: A Signal of
Misunderstanding, the Report of the US National Commission on Marijuana and Drug Abuse.”
The report concluded that cannabis had medical use, was safe, and should be removed from
Schedule I saying: “the volume of information available on the medical application of cannabis
is considerable,” “the actual and potential harm of use of the drug is not great enough to justify
intrusion by the criminal law,” and recommended that “the possession of marijuana for personal
use no longer be an offense” (The Report of the National Commission, 1972). President Nixon
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ignored these recommendations and cannabis remains Schedule I to this day, continuing the
prohibition of medical cannabis federally and effectively prohibiting medical practitioners from
prescribing cannabis (NCSBN, 2018).
Cannabis use remained restricted until 1996, when voters in California approved the first
legalization of medical cannabis. However, the federal government opposed this proposition and
threatened to revoke the prescription-writing abilities of doctors who prescribed or recommended
cannabis (Ryan et al., 2021). In 2000, this policy was challenged by a group of physicians who
prevailed in court with the ruling deciding that physicians could recommend—but not
prescribe—medical marijuana, as it was protected speech by the First Amendment (Conant vs
McCaffrey, 2000). This ruling was later defended in 2002 with a decision from the Ninth Circuit
Court of Appeals confirming that doctors could not be punished by the federal government for
discussing or recommending medical cannabis, and prohibiting the federal government from
“revoking a physician's license to prescribe controlled substances or conducting an investigation
of a physician that might lead to such revocation, where the basis for the government's action is
solely the physician's professional 'recommendation' of the use of medical marijuana." (Conant
HIV AIDS vs Walters DEA, 2002).
Since these rulings and the first legalization of medical cannabis, there has been a steady
increase in cultural acceptance of cannabis use in America with many other states following
California’s lead and Maine being the fifth state to legalize medical use (State Medical
Marijuana Laws, 2021). As of May 18, 2021, medical cannabis is now legal in some form in 46
states, the District of Columbia, Guam, the Virgin Islands, and Puerto Rico, with 18 states also
legalizing cannabis for adult recreational use, including Maine (State Medical Marijuana Laws,
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2021). It is also legal in Canada, including all provinces/territories of Canada (Understanding the
New Access to Cannabis, 2016).
Many other countries have not had the same scheduling restrictions to cannabis research
and have made major advancements impacting medical use. A most important discovery was in
1992 in Israel when Dr. Raphael Mechoulam and a team of scientists discovered the
endocannabinoid system (ECS) after isolating the first endogenous cannabinoid neurotransmitter
they named ‘anandamide,’ meaning ‘bliss’ in Sanskrit. The discovery of the ECS significantly
expanded the research on cannabis and led to a deeper understanding of the pharmacology of
cannabis, the exogenous cannabinoid which mimics endocannabinoids (Pertwee et al., 2006). By
2003, there was enough research on cannabinoids for the U.S. Department of Health and Human
Services to receive a patent US 6630507 B1 for the therapeutic use of "cannabinoids as
antioxidants and neuroprotectants," explaining that “cannabinoids have been found to have
antioxidant properties…” and “particular application as neuroprotectants...” in the treatment of
“acute ischemic neurological insults,” “chronic neurodegenerative diseases,” and “oxidation
associated diseases” (Hampson et al., 2003).
In 2015, the World Health Organization published a prominent report examining the
evidence of cannabis research and determined cannabis had many medical uses (Madras, 2015).
Soon after, the WHO’s Expert Committee on Drug Dependence recommended removing
cannabis from scheduling, acknowledging its medical utility and the need for further research,
which the United Nations recently approved in 2020 (Current scheduling recommendations
[UN], 2021).
In America, legislation to remove cannabis from scheduling has been proposed multiple
times throughout the decades and most recently in August 2021 with the “Cannabis
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Administration and Opportunity Act” advocating to remove all cannabis from scheduling to
allow regulation and tax (Fandos, 2021). It is estimated that 70% of the American public now
support the legalization of cannabis, and it is a matter of time before legislation to make it
federally legal is passed (Fandos, 2021).
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CHAPTER 3
IMPACT OF SCHEDULE I STATUS
Limits Research on Medical Cannabis
The effects of cannabis being classified as federally illegal are wide and have had a
significant impact on society medically as discussed below. It is also important to be mindful of
the social impacts as well. The aggressive enforcement of cannabis possession laws continues to
unfairly prejudice minorities and is well documented by the American Civil Liberties Union who
report people of color are still four times as likely as whites to be arrested for cannabis
possession, despite using the drug at the same rate, and are also disproportionately targeted by
SWAT teams, often resulting in violence (ACLU, 2018).
The medical impacts of the illegal status of cannabis are significant as this has
considerably impeded the advancement of research in the United States. Research is still possible
and has also been done in other countries, but restrictions from the federal government limits the
amount of the randomized-controlled trials approved in America, considered the gold standard in
medicine, which therefore limits the amount of evidence-based information providers need to
guide their practice (NASEM, 2017; Ryan et al., 2021). Most funding for cannabis research
comes from the National Institute of Drug Abuse (NIDA) whose mission is to “advance science
on the causes and consequences of drug use and addiction.” It is therefore not surprising that
most of the cannabis studies approved are those investigating the harms of cannabis (94% of all
cannabis studies approved in 2016) and less than one fifth of the studies approved are those
investigating the therapeutic properties (6% of all cannabis studies approved in 2016)
(MacDonald, 2016; NASEM, 2017).
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Even when the government does approve cannabis studies, the process to obtain cannabis
for research is known to be “cumbersome and unlike any other procedures used for drug
research” (NASEM, 2017; NCSBN, 2018). In fact, the government studies require researchers to
use either the synthetic approved versions of THC (Nabilone and Drabinol) or cannabis from
their government supply from the University of Mississippi, both of which have proven to be less
effective and lower quality than most medical cannabis (Hellerman, 2017; MacDonald,
2016). In 2016, tests on the government cannabis showed they were contaminated with mold
and yeast and had lower amounts of cannabinoids and lower potency. For example, the potency
of THC was almost two-three times lower than medical cannabis, ranging from 3-7% with the
highest level of THC at 12.4% compared with medical strains ranging from 18.7-35%
(Hellerman, 2017; MacDonald, 2016). This means that results from government funded studies
with lesser quality cannabis may offer little to no insight into the actual therapeutic and adverse
effects of medical cannabis and are less applicable in clinical practice.
As well, the research often does not encompass all available formulations of cannabis
used in medical use and often does not indicate specific dosages, duration, route, or which
chemovar was used -- meaning ‘chemical variety’ in the plant, also called ‘strains,’ which vary
considerably in their content and ratio of cannabinoids (NCSBN, 2018; Ryan et al., 2021). The
ratio of THC:CBD is a critical differentiating factor in medical use and a major contributor to
ensuring cannabis is therapeutic rather than impairing (Sulak, 2021). Though both cannabinoids
have analgesic and neuroprotective properties, they do differ -- THC has more potent analgesic,
anti-spasmodic, and sedative effects and can temporarily dull short-term memory (helpful for
severe pain, insomnia, and PTSD) while CBD has more potent anti-inflammatory, anticonvulsive, and anxiolytic effects and can increase focus and concentration (helpful for
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inflammatory pain, anxiety, ADHD) (Pertwee et al., 2006; Russo et al., 2018; Sulak, 2021).
Although there are over 25,000 studies describing the safety and efficacy of cannabis for treating
certain conditions, more RCTs are needed to provide the evidence-based specificity in which
dose/ratio/duration is best for which conditions to help providers understand how to apply this
research to clinical practice (Ware et al., 2015).
Fortunately, there are some high-quality clinical trials and resources providers can look to
for current guidance from practicing expert cannabis clinicians like the Society of Cannabis
Clinicians, a nonprofit educational and scientific society of physicians and health care
professionals dedicated to the education and research of medical cannabis use, offering a
collection of course, webinars, and research studies to guide clinical decision making, where all
articles are vetted to ensure only rigorous, unbiased, non-commercial studies (SCC Library,
n.d.). The Medical Cannabis Institute also offers accredited online medical cannabis education
for healthcare professionals and state-specific certification, developed by TMCIGlobal in
collaboration with the Society of Cannabis Clinicians (TMCI.com, n.d.). Dr. Dustin Sulak, D.O.,
an internationally renowned cannabis clinician with over eleven years in clinical practice treating
18,000+ medical cannabis patients also has a cannabis certification program and free training for
providers and patients with many articles and monthly webinars reviewing the latest research
(Healer.com). Dr. Sulak also recently released a book, the Handbook of Cannabis for Clinicians:
Principles and Practice which provides a wealth of knowledge and research on medical cannabis
for a multitude of conditions, including treatment strategies and cautions based on his extensive
research and clinical experience (Sulak, 2019; Sulak, 2021). However, most medical providers
may be unaware of these resources to educate themselves on medical cannabis use.
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Limits Access to Medical Cannabis
The illegal status of cannabis has also significantly impacted access to quality medicine
with access varying widely depending on which state patients live in and what their regulations
or qualifying conditions are (NCSBN, 2018). The Journal of Nursing Regulation lists some of
the most common qualifying conditions across all MMPs that patients receive certifications from
various states to use cannabis for: chronic pain, insomnia, neuropathies, nausea/vomiting, ALS,
Alzheimer’s, Parkinson’s, mood and anxiety disorders, arthritis, fibromyalgia, cachexia, cancer,
Crohn’s, ulcerative colitis, IBS, epilepsy, seizure, glaucoma, Hepatitis C, HIV/AIDS, migraines,
MS, muscle spasms, PTSD, sickle cell disease, terminal illness, opioid use disorder (NCSBN,
2018). Although this list gives an idea of the wide span of therapeutic uses patients are utilizing
cannabis for, not all these conditions are legal in all states (NCSBN, 2018). These discrepancies
restrict access to medical cannabis depending on which conditions are approved, even if the
patients do live in a state where it is legal. Patients in Maine have easier access to medical
cannabis than most since 2017, when recreational use was legalized and medical use was
amended to no longer require providers to state a qualifying condition for medical certification.
Instead, providers only need to deem that the patient may benefit from use and that the risks and
benefits were discussed, with the law stating that a provider need only state that “in their
professional opinion, a qualifying patient is likely to receive therapeutic or palliative benefit
from the medical use of marijuana to treat or alleviate the patient’s medical diagnosis” (Maine
Medical Use of Marijuana Act, 2017)
The few forms of cannabis available to patients who live in states without medical use or
approved qualifying conditions are the FDA approved synthetic isolated cannabinoids (i.e.,
Schedule II ‘Nabilone’ and ‘Dronabinol’, synthetic isolates of THC and ‘Epidiolex’, a purified
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isolate of CBD) proven to be less effective than whole plant cannabis (Sulak, 2021). The higher
efficacy of the whole plant cannabis is due to the synergistic effects of all 550 phytocompounds
within the plant which includes 120 identified cannabinoids and several different terpenes known
as ‘essential oils’. This synergistic effect is known as the ‘Entourage Effect’ and is wellestablished by research showing these phytocompounds have even more potent effects when
administered together than they do alone (Russo, 2011; Pertwee, 2008). A recent meta-analysis
comparing Epidiolex to whole plant CBD-rich extract which contains all the phytoconstituents of
the plant, including a small amount of THC found that 36% of patients improved with the isolate
compared to 71% with the whole plant, plus those using Epidiolex had to use dosages four times
higher leading to more adverse effects compared to those using whole plant CBD (Pamplona et
al., 2018). However, when patients live in states where medical use is not legal or end up in
hospitals that refuse to allow patients to use their medical cannabis due to fears of losing federal
funding, these lower synthetic replacements are often the only options patients have (Sulak,
2021).
Whole plant CBD is currently available to patients now that the CSA was amended to deschedule strains of cannabis with high concentrations of CBD with less than 0.3% THC (Ryan et
al., 2021). However, the market is largely unregulated like supplements and, without being
federally legal and FDA approved, is not subject to the same quality and safety standards as most
prescription drugs (NCSBN, 2018). This has led to inaccurate labeling of many CBD products. A
2017 JAMA study found only 30% of CBD sold online contained percentages of CBD within
10% of that labeled, with 26% containing little to no CBD, and almost half mislabeled and
containing contaminants (Bonn-Miller at al., 2017). Some companies have also been misleading
in their labels, for example labeling bottles by the amount of ‘hemp extract’ in the bottle (i.e., 75
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mg) rather than the amount of active cannabinoid CBD (i.e., less than 14 mg) (Bonn-Miller et al.,
2017). This mislabeling considerably changes the amount of CBD patients are getting with each
dose, leading to inconsistent and reduced therapeutic effects, if any.
Many patients and providers may not be aware of ways to ensure that cannabis products
sold online or in dispensaries contain safe and effective contents. More responsible companies
will require their products to be tested in an independent laboratory, known as ‘third-party
testing,’ to determine the exact content/amounts of each cannabinoid and terpene in each batch
and to ensure there are no contaminants like heavy metals, solvents, pesticides, yeast, or mold.
Patients aware of this laboratory testing can ask companies for the certificate of analysis, (COA)
often available on the label with a QR reader or listed on the website, to know exactly what their
cannabis product contains and to determine if it is the right product for their needs (see Appendix
A: COA). Many patients are not aware of the need to look at the COA and do not understand that
without federal oversight their product may not be safe or effective (Bonn-Miller et al., 2017;
Sulak, 2021)
In summary, the current scheduling of cannabis as federally illegal continues to restrict
high quality research for providers and access to high-quality medicine for patients. Without
evidence-based protocols, patients are left on their own to experiment and figure out doses and
ratios of medicine. Without federal oversight on products, it is also up to the patient to navigate
the unregulated cannabis market to ensure they are getting safe, consistent medicine of high
quality.
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CHAPTER 4
THE ENDOCANNABINOID SYSTEM
Before trying to understand the complex nature of the effects of cannabis, it is important
to have a deeper understanding of the endocannabinoid system (ECS) and its’ ability to produce
bidirectional effects, or opposite effects. The ECS is comprised of numerous endocannabinoids
(most notably 2-AG and AEA/anandamide) and the numerous cannabinoid receptors it binds to
(most notably CB1 and CB2) found throughout the body but most concentrated in the nervous
system (Pertwee, 2008). The ECS is one of the most important physiologic systems in the body
and performs different tasks in different tissues, but with the same overarching goal:
homeostasis, maintaining balance inside bodies despite fluctuations in external environment
(Donvito et al., 2018; Parsons & Hurd, 2015). The ECS is involved in processes modulating
pain, inflammation, mood, appetite, sleep, memory, blood pressure, etc. and is most known for
helping us relax, eat, sleep, forget, and protect our bodies from injuries or illness (DiMarzo et al.,
1998; TMCI, n.d.).
The endocannabinoids are synthesized on demand from eicosanoids and have mostly
local effects and short half-lives, degraded by fatty acid amide hydrolase (FAAH) and
monoacylglycerol lipase (MAGL) (TMCI, n.d.). Arachidonoylethanolamide (known as AEA or
anandamide) is a full agonist at TRPV1 and partial agonist at CB1/CB2, while 2Arachidonylglycerol (2-AG) is a full agonist at CB1/CB2 and is the most commonly expressed
endocannabinoid in the brain (TMCI, n.d.). These endocannabinoids are known for their
neuroprotective and neuromodulating effects -- THC mimics both AEA and 2-AG while CBD
modulates them. (Russo et al., 2018; Sulak, 2021).
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Retrograde Signaling
The main receptors these endocannabinoids bind to are CB1 receptors found mostly in
the central nervous system but also in organs (heart and lungs), muscles, glands, gonads, and
connective tissue (Elphick & Egertová, 2001). CB1s are the most highly expressed GPCRs in the
brain and are located pre-synaptically on the neuron (Pertwee, 2008). This pre-synaptic location
of the receptors means the signaling for ECS is retrograde, backwards -- a major contributor to
the wide variety of and sometimes opposite therapeutic effects cannabis can have (Pertwee,
2008). Cannabinoids can travel backward to bind with CB1 on the presynaptic neuron where
they can inhibit the neuron’s release of neurotransmitters, essentially acting as a negative
feedback loop for neurotransmission (TMCI, n.d.; Zou & Kumar, 2018). For example, if there is
too much activity in the brain, agonists at CB1 could limit the release of excitatory glutamate but
if there is not enough activity, it could limit the release of inhibitory GABA instead -- this
explains the ability of cannabis to both excite and sedate (Sulak, 2021). CB2 receptors are found
mainly in the immune system and spleen but also the liver, pancreas, bones, and skin. CB2
agonists are involved in immune cell migration and can inhibit the release of pro-inflammatory
cytokines (Pertwee, 2008; TMCI, n.d.). There are no cannabinoid receptors located in the brainstem cardiorespiratory centers which is why cannabis has no lethal dose as it cannot shut down
breathing or heart rate, like opioids can (Glass, 1997; Sulak, 2021).
Many disease processes such as migraines, fibromyalgia, and IBS are thought to be due
to a deficiency in our ECS, which can be impaired by chronic stress and poor diet, especially the
standard American diet, which is low in Omega 3 fatty acids, a key ingredient needed to build
endocannabinoids. (McPartland et al., 2014; Russo et al, 2018; Sulak, 2021;). Research on
modulating the ECS to improve health shows that levels of endocannabinoids can be increased
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naturally through a healthy lifestyle, most notably diets rich in vegetables and omega-3s, regular
exercise, and stress-reduction strategies such as yoga and meditation (McPartland et al., 2014).
Clinical studies support this and suggest the runner’s high may be due to increased
endocannabinoid levels rather than endorphins, where 30 minutes running produced higher levels
of anandamide, more quickly than endorphins, and stayed elevated long after the endorphins
were gone (Heyman et al., 2012; Sparling et al, 2003). However, animal studies on forced longterm exercise showed endocannabinoid levels increased but stayed elevated to the point where
CB1 receptors downregulated, giving insight into how conditions that put a lot of stress on our
bodies might lead to a deficiency of our ECS (McPartland et al., 2014). The other way to
support the ECS is with exogenous supplementation through cannabis which contains
phytocannabinoids that mimic endocannabinoids.
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CHAPTER 5
PHARMACOLOGY OF CANNABIS
The cannabis plant contains over 550 phytocompounds, 120 of which are identified as
phytocannabinoids, and the chemovar (chemical variety) of each plant can vary considerably
depending on its chemotype -- type of cannabinoids within and the amounts or ratios of each
(Nahler et al., 2019). When selecting a chemovar for medical use, the most important compounds
to look at are THC and CBD (their amounts and ratio to each other), followed by the kind of
terpenes which can also influence the plant’s ability to sedate (i.e., linalool, myrcene) or
stimulate (i.e. limonene) (Russo et al, 2018; TMCI, n.d.).
Pharmacodynamics
THC is the cannabinoid most known for cannabis’ psychoactive effects, but it is also a
powerful medicine responsible for some of the most common effects cannabis is used for:
analgesic, anti-spasmodic, anti-emetic, induces sleep, and appetite stimulant effects. It can also
cause significant side effects (i.e., hypotension, tachycardia, and euphoria) and significant
adverse effects in higher doses (anxiety/paranoia, impaired short-term memory, and delayed
motor coordination) (TMCI, n.d.). Though an excess dose of THC cannot be lethal, it can be
very unpleasant and cause rapid heart rate, mental confusion, and paranoia that can last from 424 hours. It is generally associated with ingestion of edibles that have a delayed and erratic onset
leading some patients to ingest higher doses than needed (Sulak, 2021). This is uncommon in
medical use that more carefully controls the concentration of THC and uses CBD that mitigates
the peak and onset of THC. Cannabis clinicians recommend mitigating the intoxication with
CBD 1-2 times the dose of THC that was ingested (Russo & Guy, 2006; Sulak, 2020).
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The other major phytocannabinoid that THC works best in conjunction with is CBD,
which is rapidly gaining interest in medical use due to its wide variety of therapeutic properties
and high safety profile (TMCI, n.d.). CBD is non-intoxicating so is not regulated internationally
and is often prescribed in low doses in other parts of the world for its neuroprotective antioxidant
properties (Sulak, 2019). CBD is a negative allosteric modulator at CB1, meaning it can prevent
THC from binding which is how CBD mitigates the peak and side effects of THC, a key
component to medical use (Pertwee, 2008; Russo et al., 2018; Sulak, 2021). Studies in cell
models show that CBD also has over 65 pharmacologic targets which explains its wide variety of
effects: it is a partial agonist at CB2 which is likely how CBD reduces inflammation and
modulates the immune system; an indirect agonist at 5-HT1A which is likely how CBD reduces
anxiety, nausea, and improves focus; an agonist at TRPV1 so can also reduce pain; an antagonist
to the mu-opioid receptors which is likely how CBD can reduce opioid cravings and use; also
can inhibit uptake of neurotransmitters NE, DOP, SER, GABA, and anandamide which is likely
how CBD is beneficial for many mental health issues (Ibeas et al, 2015; Nahler et al., 2019;
Russo et al., 2018). CBD is also well-tolerated with the only side effects being decreased appetite
and, at higher doses > 100 mg/day, can cause sedation and diarrhea. (Russo et al., 2018; Nahler
et al., 2019).
There is also promising research on the other phytocannabinoids as well, especially
THCA and CBDA, the non-intoxicating precursors to THC and CBD that exist in the raw plant
before it is decarboxylated. These have been shown to have powerful therapeutic effects of their
own (anti-inflammatory, anti-emetic, anti-neoplastic) in minute amounts and contribute to the
entourage effect, enhancing the effects of THC and CBD (Moreno-Sanz et al., 2016; Russo et al.,
2011; Sulak, 2021). Clinical evidence is showing they have much higher bioavailability than
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THC and CBD, up to 5-10 times the amount (Sulak, 2020). In clinical practice many elderly
patients will use THCA and CBDA by steeping a pea-sized piece of the raw flower in tea for a
few minutes to get the anti-emetic and anti-inflammatory effects of the plant without the
psychoactivity (Sulak, 2021).
Pharmacokinetics
The pharmacokinetics of medical cannabis vary greatly, especially with different
methods of administration, with oromucosal being the most preferred in medical use and
inhalation only recommended for acute relief, with a flower vaporizer only and no smoking
(Sulak, 2021; TMCI, n.d.). The absorption for oromucosal ranges from 6-15% which is less than
absorption with inhalation which ranges from 10-35%. Oromucosal bioavailability, however, can
be enhanced up to five times with ingestion of food containing fats since both THC and CBD are
lipophilic compounds, and it can also be enhanced by keeping it sublingual or buccal for 1-2
minutes before swallowing. The peak concentration for oromucosal can vary widely from 1-6
hours but the duration of effects can last up to 12 hours, on average 6-8 hours. This makes
sublingual delivery ideal for medical use, able to be dosed two to three times a day.
Once cannabis is swallowed it is metabolized in the liver by the cytochrome P450
enzymes with the most common for both THC and CBD being CYP3A4 and CYP2C9, and 2C19
for CBD, with the average half-life of THC being 10-17 hours and CBD being 1-2 days. Drugs
that are metabolized by the same enzymes cannabis is such as warfarin and anti-epileptic drugs
like clobazam should be monitored as doses may need to be decreased with regular use of
medical cannabis (Damkier et al., 2018). Providers can screen for drug-drug interactions on
Medscape by using the terminology of the FDA approved synthetic versions of cannabis such as
‘Nabilone’ for THC and ‘Epidiolex’ or cannabidiol for CBD (Sulak, 2021).
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Elimination is slow due to accumulation in adipose tissue and some studies show
cannabis can be re-released with exercise even weeks later termed the ‘depot effect.’ However,
80-90% is excreted within five days, with 20-35% eliminated in urine and 65-80% eliminated in
feces. Although inactive metabolites can be detected in urine for up to 12 days. (Pertwee, 2008,
Sulak, 2021; TMCI, n.d.)
Inhalation, on the other hand, avoids first pass metabolism so peaks in 1-3 minutes,
causing 1-2 times higher peak serum concentrations than oromucosal, which is why adverse
effects are much more common with inhalation. As well, the peak effects from inhalation
decrease rapidly in 30 minutes lasting a total of 1-3 hours, which is why inhalation is only
recommended in medical use for rapid relief of acute symptoms like with panic attacks.
Side Effects
Medical cannabis can produce varying side effects and are within the range tolerated for
other medication with the most common side effects being dizziness, dry mouth, sleepiness,
euphoria, and, with higher doses, disorientation, impaired balance and short-term memory,
dysphoria, anxiety, confusion, paranoia, nausea, and vomiting (Whiting et al., 2015). A review
of 23 RCTs found there was no higher incidence of serious adverse events in medical cannabis
users compared with control, but there was a higher incidence of non-serious side effects with
dizziness being the most common and dry mouth the next (Wang et al., 2008).
Impacts on Side Effects
Clinical experience has shown that many of the adverse effects can be avoided with the
proper dosing and chemovar and are most often due to doses being too high, common with THC
over 5-10 mg and CBD over 50-100 mg (Pertwee, 2008; TMCI, n.d.; Sulak, 2021). Cannabis
clinicians caution patients against building tolerance which increase their risk for side effects

24

since patients start increasing their doses. Tolerance occurs when continued stimulation of
cannabinoid receptors leads to saturation, desensitization, and down-regulation, more common
with use of higher THC ratios as studies show 15% lower CB1 receptor availability in men using
THC regularly (Sulak, 2021). Patients can actively avoid tolerance by abstaining from cannabis
for 1-2 days to allow receptors to re-sensitize and up-regulate and can often restart at 50-60%
reduced doses. The other less common causes of side effects are due to delivery, most
particularly inhalation which causes the highest peak serum concentration and chemovar, most
particularly when the ratio is too high in THC which increases side effects and too low in CBD
which can mitigate the effects (Sulak, 2021). Dr. Sulak’s Healer site offers excellent videos to
help patients find their proper dose and chemovar, avoid side effects and tolerance, and
resensitize receptors (Sulak, 2019).
Biphasic Dose-Response and Bidirectional Effects
Many notable adverse effects reported such as anxiety, nausea, vomiting, and dysphoria
are the very symptoms well-known to be relieved by cannabis. This bidirectional phenomenon is
related to the homeostatic function of the ECS and its retrograde signaling which allows the ECS
the capacity to influence physiology in opposite directions in order to maintain cellular balance
(Pertwee et al., 2008; Sulak, 2021). The other factor contributing to this bidirectional
phenomenon is the biphasic dose-response effect of cannabis -- where at first increased doses
cause increased effects, like other mono-phasic medications. Beyond a certain threshold dose,
the receptors become saturated and start to down-regulate and increasing the doses will instead
lead to decreased positive effects while worsening the side effects (Russo et al., 2018; Sulak,
2021). Recent research on cannabis hyperemesis syndrome (CHS) demonstrates this biphasic
dose-response effect. Although cannabis is used to relieve nausea and vomiting, long-term
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heavy use or for those with genetic mutations that decrease the breakdown of cannabis can
actually cause intractable nausea and vomiting that can only be resolved by cessation of cannabis
use for weeks or months. (DeVuono et al., 2020; Russo et al., 2021).
Proper Dosing
Clinical experience demonstrates this biphasic dose-response can be mitigated with
proper dosing and dosing strategies to ensure patients do not go beyond their threshold dose or
build tolerance (Sulak, 2021). Cannabis clinicians always advise patients to find their proper
dose by “Starting Low” at the lowest doses (1-2 mg) and “Going Slow” only titrating up every 35 days to give receptors time to adjust and to fully feel the effects (Sulak, 2021). Clinical trials
on Nabiximols revealed the importance of finding the right dose as earlier trials with Nabiximols
yielded significant higher rates of adverse effects prior to adopting this slower and lower dose
titration schedule (Barnes et al., 2006; Sulak, 2021). Cannabis clinicians also educate their
patients about the biphasic dose-response of cannabis, explaining that if they start to notice side
effects, then they are probably beyond their threshold dose and need to decrease the dose; but if
they start to notice loss of effects, that it is usually a sign their ECS has been overstimulated and
tolerance is being built. At this point, clinicians recommend patients abstain completely for a day
or two to resensitize and upregulate receptors. (Sulak, 2020; Sulak, 2021; Russo et al, 2021)
Summary of Cannabis Pharmacology
In summary, it is important to understand that cannabis does not adhere to the same set of
pharmacology rules as other medications due to the retrograde signaling of the ECS and capacity
to produce bidirectional effects. Providers need to be aware that most of the adverse effects from
cannabis can easily be avoided by using the proper dose, dosing strategies, chemovar, delivery
and by avoiding building tolerance.
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CHAPTER 6
STRATEGIES TO MINIMIZE HARM AND MAXIMIZE BENEFIT
Providers need to be made aware of the following strategies discussed above and
summarized below that can minimize harm and maximize benefit for patients using medical
cannabis:
•

DO NOT SMOKE CANNABIS. Inhalation should be with flower vaporizer only and
only for rapid relief of acute symptoms.

•

CHOOSE WHOLE PLANT CANNABIS products that are LABORATORY TESTED,
ideally with third party testing to know the exact contents of medicine.

•

CBD IS NON-INTOXICATING. There is conclusive evidence CBD is safe and effective
for treating inflammation, mental health conditions, addiction, seizures, mitigating side
effects from THC, hepatic illness, pain, nausea, and vomiting, without side effects. For
those more vulnerable to impairments such as the elderly and adolescent population,
consider CBD-rich cannabis first.

•

THC CAN BE INTOXICATING. THC is most effective for pain, sleep, spasms, nausea,
and vomiting but can be intoxicating and has significant dose-dependent side effects,
especially in doses greater than 5-10 mg which can temporarily increase heart rate,
anxiety, sedation, and impair memory and balance.

•

CAUTION IF USING THC in the following conditions:
o

Unstable heart disease or use of heart medications (risk: MI)

o

Severe psychiatric illness (risk: worsening of bipolar symptoms or earlier onset
schizophrenia for those predisposed)

o

Hepatic illness with active inflammation and scarring (risk: increased fibrosis)
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o

Elderly (risk: falls due to dizziness and impaired motor coordination)

o

History of substance-abuse (risk: CUD, especially with inhalation)

o

Pregnant/Lactating (risk with inhalation and heavy use: dysregulation of ECS)

o

Immunocompromised (risk with inhalation: lung infection if contaminated
product).

•

CHECK FOR DRUG-DRUG INTERACTIONS on Medscape or drugs.com.

•

FIND THE RIGHT DOSE, critical to maximize benefits and minimize side effects.
o

START LOW, (i.e., 1-5 mg for CBD, 1 mg for THC) and assess for effects.

o

GO SLOW, titrate up every 3-5 days if needed.

o

IF SIDE EFFECTS, decrease dose.

o

IF LOSS OF EFFECTS/TOLERANCE, abstain for 1-2 days to resensitize
receptors.

•

USE OROMUCOSAL delivery for longer duration and measured and controlled dosing.

•

AVOID TOLERANCE AND HEAVY USE (risk: CUD and increased side effects).

•

AVOID DRIVING or operating machinery until response to strain/dosage determined.

•

STORE MEDICAL CANNABIS in child-proof container.

•

COMMUNICATE with medical providers for guidance on proper dose and ratio of
THC:CBD as evidence-based research is emerging rapidly.
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(Sulak, 2021)

CHAPTER 7
CLINICAL EVIDENCE ON MEDICAL CANNABIS
There is a considerable amount of research on the clinical evidence of medical cannabis
of various conditions, but the two most comprehensive reports are those from the World Health
Organization and the National Academies of Sciences, Engineering, and Medicine (NASEM),
the latter one what the educational presentation was mostly focused on, updated with recent
research as appropriate (Madras, 2015; NASEM, 2017).
NASEM Report
After reviewing more than 10,000 studies, the NASEM committee reached nearly 100
conclusions, which supported the medical utility of cannabis and determined that the medical
conditions patients used medical cannabis for had strong evidence 86% of the time (NASEM,
2017; Rapaport, 2017).
Due to the political restrictions on research discussed earlier, the committee concedes
their results are generalized and limited by the scope of this research and lack of differentiation
between medical use and recreational use (NASEM, 2017). The report also is limited by the
studies that were available at the time, which were mostly focused on spasticity, nausea and
vomiting, anorexia, and chronic pain, and therefore do not address many of the qualifying
conditions patients use cannabis to treat (NCSBN, 2018).
The report also lacks information critical for providers caring for patients in clinical
practice, such as dosage, method of administration, duration, frequency, chemovar/ratio of
THC:CBD, drug interactions, etc. There are some conclusions for which the committee was able
to distinguish the kind of cannabis or method used and included these distinctions in parentheses
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when available. Despite the limitations in specificity and for conditions, the committee’s
conclusions on the evidence at the time offers valuable insight into the medical use of cannabis.
Definitions of Evidence
Before reviewing the conclusions, it is important to understand the terminology provided
by the committee to clarify the level of evidence concluded. The level of evidence is ranked from
conclusive, substantial, moderate, limited, to insufficient with ‘conclusive’ being strong evidence
from RCTs that support cannabis as an effective or ineffective treatment with many supportive
findings from good-quality studies and no credible opposing finds or evidence of chance, bias,
and confounding factors, meaning a firm conclusion can be made. ‘Substantial’ is similar to
conclusive but with minor limitations including chance, bias, and confounding factors that
cannot be ruled out. ‘Moderate’ has some evidence with several findings from good- to fairquality studies but chance, bias, and confounding factors cannot be ruled out, while ‘limited’
means there is weak evidence from fair-quality studies and conclusions can be made but with
significant uncertainty due to chance, bias, or confounding factors. ‘Insufficient’ means there is
not enough evidence to support that cannabis is either an effective or ineffective treatment due to
mixed findings or single poor studies with significant uncertainty due to chance, bias, and
confounding factors (NASEM, 2017).
Safety Profile of Medical Cannabis
Non-Lethal, Non-Toxic
The committee’s conclusions regarding the safety of cannabis determined that cannabis is
non-lethal and non-toxic with “no evidence of any deaths due to cannabis use or overdose”
(NASEM, 2017). This is supported by extensive research on the pharmacology of cannabis
revealing that there are no cannabinoid receptors on the cardiorespiratory receptors meaning
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cannabis cannot stop breathing or heart rate, unlike opioids can (Glass et al., 1997;
Grotenhermen, 2004; Russo & Marco, 2017; Sulak, 2020). Other research in animal studies, one
giving monkeys 9000 mg/kg of THC, over 180 times the maximum human amount, has “failed
to find a lethal acute dosage of cannabis, and have found that the doses of long-term cannabis
required to produce toxicity and death in animals were so high it would be nearly impossible for
a human to consume such quantities via ingestion or inhalation” (Joy et al., 1999; Sulak, 2020;
Thompson et al., 1974). Providers may be more confident discussing and recommending medical
cannabis when they realize that there is conclusive evidence that cannabis is safe, non-lethal, and
non-toxic with no evidence of death or overdose.
Not a Gate-Way Drug
Regarding cannabis being a gate-way drug, the committee found ‘limited evidence’ that
cannabis “led to tobacco use or other illicit substances,” or “increased the risk of addiction”
(NASEM, 2017). This is supported by current research showing that CBD has anti-addictive
effects that can help treat disorders of addiction including tobacco use, recently confirmed by
RCTs using CBD for opioid use disorder (Hurd et al., 2019; Nahler et al., 2019; Prud’homme et
al., 2015). It may help providers counter the stigma of cannabis to know there is limited evidence
that cannabis is a gate-way drug or increases addiction risk, and this was a myth started by
Aslinger’s campaign to criminalize cannabis, which he later admitted in emails was fabricated,
that has unfortunately been propagated throughout the years (Bearman, 2017; Earleywine, 2005;
Wing, 2014).
Low Risk for CUD with Medical Use
As for the question of cannabis having a high risk of abuse, known as cannabis use
disorder (CUD), the committee found an association with CUD and the use of higher THC and

31

certain risk factors. They found there was ‘substantial evidence’ for the ‘risk of problem
cannabis use’ in those who are male and smoke cigarettes, and ‘moderate evidence’ for those
who are frequent heavy users, have combined use of nicotine and abused drugs, have childhood
sexual abuse and parental substance use, poor school performance, antisocial behaviors, and
initiate cannabis at an earlier age (NASEM, 2017). However, the committee did not differentiate
between medical use and recreational use which recent research clarifies does differ in the risk
for abuse.
Long-term studies of patients in the UK, Germany, and Switzerland using Nabiximols
(1:1 THC:CBD) for multiple sclerosis showed no sign of abuse, dependence, or diversion in
30,000 patient-years of recorded usage (Russo et al., 2015). This is most likely due to the
inclusion of CBD which has an established low risk for addiction as CBD does not produce
euphoria or stimulate the reward center in the brain and can block THC’s ability to do this -many studies have used CBD to successfully reduce addiction and cravings in many disorders
including tobacco, alcohol, and opioid use (Hurd et al., 2019; Prud’homme et al., 2015; Russo &
Marco, 2017; Sulak, 2021). Studies analyzing the impact of medical cannabis legalization on
CUD compared to recreational legalization found that medical cannabis legalization has not
increased the risk of abuse and that the increased risk of abuse is only associated with
recreational legalization and use of higher THC cannabis, which unlike CBD, does stimulate the
reward centers in the brain, especially with inhalation which increases the peak serum
concentration in the brain (Cerda, 2020; Sulak, 2021; Williams, 2017).
Low Risk for Dependence
To put this risk of abuse in perspective, research has found that 4% of those who use
cannabis meet criteria for CUD, with the addictive potential of cannabis (i.e., cravings or use
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despite problems from use) similar to caffeine, usually occurring with heavy and prolonged use
(Anthony, 2001; Joy et al., 1999; Russo et al., 2015; Sulak, 2021). As for the risk of dependence
with recreational cannabis use (i.e., withdrawal symptoms with cessation), it is estimated to be
9%, compared to alcohol at 15% and nicotine at 32% (Anthony et al., 1997; Lopez-Quintero et
al., 2011; Patel & Marwaha, 2021). A risk of dependence with cannabis use exists, but it is mild
and almost two times lower than alcohol and almost four times lower than nicotine. The
withdrawal symptoms from cannabis are also comparable to caffeine (i.e., irritability,
restlessness, sleep disturbances due to strange dreams, decreased appetite) and are usually mild
due to the long half-life of cannabis (t ½ 1-2 days) and occur one to two days after abrupt
cessation, peak in two to five days, and resolve in one to two weeks (D’Souza et al., 2016;
Grotenhermen, 2003; Huestis, 2007; Sulak, 2020).
Increased Risk for Injuries with Driving and Accidental Ingestion
The committee did find “substantial evidence” that cannabis use “increased risk for
driving accidents (MVA)” and “increased risk of overdose injuries due to accidental ingestion in
children.” Since CBD is non-impairing, these risks are only associated with the use of higher
THC cannabis. Some meta-analyses of the risk of MVA with cannabis are inconclusive, with
some showing no risk of MVA and others showing increased risk of low-moderate magnitude
with an odds-ratio (OR) of 1.36, compared with the risk of texting OR of 2.22, which is likely
due to the dose, route, ratio to CBD, and patient tolerance, all critical factors influencing
impairment (Hostiuc, 2018). There is no standard breath, urine, or blood test to determine
intoxication because of these confounding factors, but roadside sobriety tests can be used to
measure impairment (Armentano, 2013). Countries who have legalized recreational use like
Canada have countered this risk by granting law enforcement more authority to conduct impaired
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driving tests based not on drug level but functional impairment (Williams, 2018). Providers need
to be aware of the increased risk for MVA with cannabis use and instruct patients not to drive or
operate heavy machinery until they know their response to the chemovar and dosage, cautioning
patients that THC can impair motor coordination and concentration, especially in new users,
dose increases, and with inhalation that increases serum peak concentration (Sulak, 2020).
Uncertain Risk for Prenatal, Perinatal, Neonatal Exposure
In regard to prenatal, perinatal, and neonatal exposure to cannabis, there was ‘insufficient
evidence’ to make conclusions in regard to pregnancy and child outcomes since the studies
linking cannabis to premature birth or childhood leukemia were low quality and did not control
for confounders. There was ‘substantial evidence’ that smoking cannabis during pregnancy is
linked to lower birth weight in the offspring (NASEM, 2017). Although smoking cannabis is not
recommended in medical use, it is still important to assess the effects of cannabis itself in
pregnancy, especially considering that approximately 1 in 25 women use cannabis during
pregnancy (Alshaarawy & Anthony, 2019.)
Most of the studies on pregnancy at the time of the NASEM report were limited to
observational data and did not control for alcohol or tobacco use making it difficult to accurately
assess risks. A recent meta-analysis that did control for smoking exposure found there was no
association between cannabis use in pregnancy and lower birthweight, confirmed by two other
recent studies (Connor et al., 2018; Ko et al., 2018; Sturrock et al., 2020). Recent research on
effects for offspring have found that cannabis is not teratogenic, but that THC does cross into the
placenta and is excreted into breast milk, up to 2.5% of THC per kg of weight of maternal dose
with inhalation (Baker et al., 2018). For example, if a pregnant woman weighs 60 kg and
smokes 30 mg of THC (0.5 mg/kg), her 5 kg fetus might be exposed to 0.0125 mg of THC.
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Although this level seems insignificant, especially considering levels of natural 2-AG in breast
milk are found to be 119-431 ng/mL, it is possible that heavy use of THC could downregulate or
disrupt ECS signaling that is critical in developing brain (Bertrand et al., 2018; Gaitan et al.,
2018; Grant et al., 2018; Sulak 2021).
The American Academy of Pediatrics advises avoiding cannabis during pregnancy and
lactation but does not recommend stopping or discarding milk as the benefits of breast-feeding
are so clear and the risks of phytocannabinoids so uncertain (Ryan et al., 2021). Most cannabis
clinicians follow the AAP guidance of not recommending cannabis in pregnancy and lactation,
and only support medical cannabis use (i.e., lowest dose, ratios higher in CBD, oral delivery
only) when the benefits clearly outweigh the risks, such as with hyperemesis gravidarum,
chronic pain, and PTSD -- conditions that cause high levels of maternal stress and require
teratogenic medications to treat, but respond well to low-dose medical cannabis (Sulak, 2021).
Summary of Safety Profile
To summarize the safety concerns of cannabis, providers need to be aware that cannabis
is very safe. It is non-fatal, non-toxic, not a gate-way drug, and not addictive. Instead, providers
should caution patients that there is a 4% risk of CUD and 9% risk of dependence in patients
using THC long-term, with increased risk in those who use inhalation, are male, smoke
cigarettes, started at an earlier age, and have a history of substance abuse or psychiatric
conditions. Providers should also be instructing patients not to drive while impaired, to always
keep their medical cannabis in child-proof containers, and to avoid use in pregnancy and
lactation without first consulting their provider.
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Adverse Effects: Cardiovascular, Pulmonary, and Psychological
Regarding the risk of adverse effects, the committee found no evidence of risk for organ
damage but did find evidence, expanded upon by current research, of adverse effects increased in
certain conditions for primarily three systems: cardiovascular, pulmonary, and psychological
(NASEM, 2017; TMCI, n.d.).
The cardiovascular adverse effects from cannabis are associated with inhalation of THC
in those with cardiovascular disease. It is well established that cannabis can temporarily increase
heart rate and decrease blood pressure which for most patients is mild and tolerable, but, in those
with severely unstable heart disease who cannot handle the increased load, these effects could be
harmful and increase the risk of myocardial infarction (Naliboff et al., 1976; Russo, 2015; Sulak,
2020). However, a recent systematic review of non-clinical studies has shown that CBD can have
cardioprotective effects protecting the heart from damage of heart attacks with one study
showing that very-low doses of THC may also be cardioprotective (Shayesteh et al., 2019;
Waldman et al., 2013).
The pulmonary adverse effects of cannabis are associated with smoking which is not
recommended in medical use as there is substantial evidence that smoking cannabis worsens
respiratory symptoms - increasing cough, sputum production, and risk for upper respiratory
infections - but does not increase shortness of breath or the risk of lung cancer (NASEM,
2017). Smoke is well known for containing toxins and carcinogens which can damage airways
and is not recommended as a delivery method in medical use, but cannabis itself is found to have
bronchodilatory and anticarcinogenic effects (Sulak, 2021; Whiting et al., 2015). The respiratory
effects from smoking cannabis were found to be temporary, improving after quitting smoking,
with no risk of chronic bronchitis compared to nonsmokers at 10 year follow up (Tashkin, 2013).
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After controlling for tobacco exposure, several large data sets on heavy cannabis smokers do not
show evidence of COPD even after 20 joint-years or increased rates of upper and lower
respiratory cancers compared to those who do not smoke cannabis which is thought to be due to
the anti-inflammatory and anti-carcinogenic effects of cannabinoids counteracting the toxins
(Hashibe et al., 2006; Whiting et al., 2015; Sulak, 2021).
Regardless, smoking cannabis is still not recommended as there have been several cases
of spontaneous pneumothorax and some cases of pulmonary aspergillosis in
immunocompromised patients from smoking contaminated cannabis. The other significant
concern with inhalation of cannabis is E-cigarette or vaping product use-associated lung injury
(EVALI) which is thought to be due to diluents in vaping cartridges, especially Vitamin E
acetate (Dinakar & O’Connor, 2016; Raber et al., 2015; Ryan et al., 2021). As of Feb 2020,
there were 2,807 cases of EVALI hospitalizations in America and 68 deaths, with 82% involving
THC-containing products (Sulak, 2021). Although these are associated with the use of Vitamin E
acetate, there are other harmful compounds that have been found in these vaping concentrates
such as butane, pesticides, metals, and the flavorings with propylene glycol or glycerol which
increase the risk of formaldehyde production and carcinogenic risks (Dinekar & O’Connor;
Raber et al., 2015; Sulak, 2021).
Due to these concerns, it is critical that providers instruct patients not to smoke cannabis
or vape cartridges, and if they need rapid relief from acute symptoms, then they should only
inhale from a flower vaporizer that vaporizes flowers, preferably third-party tested to ensure no
contaminants (Sulak, 2020; Sulak, 2021).
The final concern for adverse effects found by the committee and further clarified by
recent research is the psychological effects of cannabis. The committee found many results,
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sometimes seemingly contradictory, but concluded there was: ‘substantial evidence’ that
frequent use of THC increases the risk of earlier onset of schizophrenia in those predisposed, but
‘moderate evidence’ of ‘better cognitive performance for those with psychotic disorders’; and
‘moderate evidence’ that heavy cannabis use can increase symptoms for those with bipolar
disorder and increase suicidal ideation, though some studies showed improved symptoms with
cannabis use; ‘moderate evidence’ that THC can temporarily impair learning and memory, but
‘limited evidence’ of long-term impairment to academic achievement or social functioning, and
in some studies using CBD improved focus and concentration (NASEM, 2017). The next
section on the impact of dose and ratio on the psychological effects with medical cannabis use
will help to elucidate these seemingly contradictory findings.
Considerations for Psychological Effects
Bidirectional Effects. The concept of bidirectional effects and biphasic dose-response is a major
contributing factor in many of the psychological adverse effects from cannabis. For example,
anxiety has been found to be relieved with proper doses and ratios with lower THC, but higher
doses of THC have been found to exacerbate anxiety, even to the point of paranoia and panic
attacks (Russo et al., 2015). Due to the high number of cannabinoid receptors in the brain, it is
not surprising that there are several potential acute central nervous system effects with cannabis
use. Some of these can be positive (anxiolytic and anti-psychotic effects associated mostly with
CBD), and some negative (impaired short-term memory and anxiogenesis, associated with
higher levels of THC (Russo et al., 2015). The negative psychological effects can usually be
avoided with the proper dosing and ratio as is done in medical use and discussed above.
Lower Risk with Medical Use. Recent research investigating the effects of cannabis on
psychological or cognitive disorders supports the benefits of medical use compared to
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recreational use (Sulak, 2021). A 2017 comprehensive systematic review evaluated studies of
medical cannabis for outcomes related to anxiety, depression, and neurocognition. The first
conclusion was that mental health is a prominent reason for seeking medical cannabis, however,
there is far less literature on medical use of cannabis and mental health outcomes compared to
that of nonmedical use (Walsh et al., 2017). The other conclusions were as follows: all of the 8
cross-sectional studies reported anxiolysis; 7 out of 9 studies on depressed mood noted
improvement in depression and pain; preliminary evidence shows potential for treating PTSD
and addiction; one study showed a positive association between depression severity and CUD;
and the use of medical cannabis does not increase harm to self or others (Walsh et al., 2017).
Long-term data on adverse effects from medical use of Nabiximols trials collected by
observational registry on 941 pts with 2,214 patient-years of exposure showed 6% of the patients
experienced psychiatric adverse effects (depressed mood, anxiety), with 2% having suicidal
ideation, but no evidence of abuse, dependence, or long-term cognitive impairment (Etges et al.,
2016).
Benefits May Outweigh Risks. Though these risks are low, they still must be considered in
those with mental health issues more vulnerable to the risk of mood dysregulation. However,
recent studies on medical use show the benefits of using cannabis for mental health issues may
outweigh these risks, especially considering that traditional medications for mental health are not
very effective and have adverse effects leading to noncompliance (Pinto et al., 2020). The first
neuroimaging study of twenty-two patients using medical cannabis (for pain, anxiety, PTSD,
sleep) showed their brain activity normalized after three months of treatment with medical
cannabis, looking similar to healthy controls, and also noted reported improvements in task
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performance, impulse control, sleep, quality of life, and a decrease in use of conventional
medications including opioids (Gruber et al., 2018)
The studies using CBD for mental health issues show high efficacy as well, with a recent
systematic review on CBD showing there is promising evidence on CBD’s potential to be a
novel treatment for mood disorders as they have a different mechanism of action than the less
effective conventional antidepressant medications which only target monoaminergic pathways
(Linge et al., 2016; Pinto et al., 2020). This was confirmed by another 2020 systematic review
saying CBD and Nabiximols were helpful in alleviating symptoms of cannabis-related disorders,
schizophrenia, social anxiety disorder, and comorbidities of autism and attention deficit disorder
with moderate recommendation (Khan et al., 2020). Preclinical evidence shows the potential of
CBD to reduce anxiety in PTSD, generalized anxiety disorder, panic disorder, obsessivecompulsive disorder, and seasonal affective disorder, with clinical trials finding 300-600 mg
CBD effectively reduced anxiety (Blessing et al., 2015). A recent case series on anxiety found
CBD doses ranging from 25-275 mg reduced daily anxiety scores for 79% of the patients, with
most finding improvement at only 25 mg (Elms et al., 2019).
Caution with Bipolar Disorder and THC: Research on THC shows that low dose THC (less
than 7.5 mg) may have anxiolytic effects, but higher doses (12.5 mg and over) increase anxiety,
and more sensitive patients may feel anxiety even at doses over 5 mg (Cuttler et al., 2018). This
emphasizes the importance of selecting the right ratio and dose and gives insight into
contradictory findings that nonmedical use of cannabis may exacerbate bipolar symptoms, but
other times is relieved by it (NASEM, 2017; Walsh et al., 2017).
A 2020 systematic review concluded that CBD shows potential to relieve symptoms of
bipolar disorder, however, more research is needed before recommending CBD as a treatment,
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especially considering the bidirectional effects of CBD where lower doses are alerting but higher
can be sedating (Pinto et al., 2020). As well, the risk may not be worth the benefit considering
there was quality evidence showing heavy use cannabis can increase symptoms of mania and risk
for new onset symptoms up to three-fold (Gibbs et al., 2015). In summary, providers should be
aware that caution is warranted for patients with bipolar disorder using medical cannabis and
best avoided until further research and clarification.
Caution with Schizophrenia and THC. The current research on schizophrenia clarifies that
cannabis use is associated with, but not causative, of the earlier onset but only in patients with
heavy use and high dose THC and who are genetically predisposed (Frisher et al., 2009;
Hickman et al., 2009; Ksir & Hart, 2016). The research also found the incidence to be very low:
1 case in 2,800 heavy cannabis users ages 20-24 (the highest risk group), and 1 case in 10,000
light cannabis users in the same age group (Ksir & Hart, 2016). Furthermore, recent research has
shown CBD can be very effective in treating the symptoms of schizophrenia: one RCT showed
1000 mg/d CBD improved symptoms of schizophrenia in 79% of patients using over 6 weeks,
and other RCTs showed 200-800 mg/d CBD was more effective than amisulpride at reducing
symptom severity with fewer extrapyramidal side effects (Gururajan & Malone, 2016; Leweke,
Mueller, Lange, & Rohleder, 2016; McGuire et al., 2018). Again, this highlights how careful
selection of dose and ratio are key to avoiding bidirectional effects with cannabis, especially in
those with more severe mental health issues.
Caution with Cognition and THC: Research investigating the cognitive impairment with
medical cannabis also shows that the impairment is not associated with medical use and is not
long-term. However, the use of high dose THC can impair recall for sometimes weeks,
especially in adolescents. An eight-year study of 2,404 patients using cannabis showed no long-
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term impact to cognitive function in all domains except for recall which did return to baseline but
after a month of cessation (Tait et al., 2011). A recent review of RCTs showed THC can cause
mild residual cognitive effects (i.e., working memory, processing speed, and executive functions)
and can last days to weeks for some adults, longer in adolescents and longer with use of higher
doses (Bourque & Potvin, 2021). However, studies on the impact of ratios higher in CBD
showed CBD had protective effects against the cognitive impairments of THC and can also
improve focus and concentration (Colizzi & Bhattacharyya, 2017; Kahn et al., 2020). Providers
need to be aware that medical cannabis does not cause permanent cognitive impairment in adults,
but heavy use of THC can have residual effects on short-term memory that could last weeks,
especially in adolescents and those using higher doses of THC. However, providers should also
be aware that CBD can protect against these effects and improve focus and concentration, again
emphasizing the importance of dose and ratio selection, especially in adolescents.
Recommendations for Doses/Ratios: In summary, providers should be aware that more
research is urgently needed on the use of medical cannabis for mental health issues but that
current research demonstrates its potential to improve symptoms especially for anxiety and mood
disorders and especially with moderate-high doses of CBD (25-600 mg). Providers should also
be aware that patients with a personal history of bipolar disorder should avoid heavy use and
high dose THC due to the risk of exacerbation of bipolar symptoms, and though CBD may have
potential to reduce bipolar symptoms more research is needed before recommending. Providers
should also be aware that patients with a family history of schizophrenia have an associated risk
of earlier onset with heavy use and high dose THC but may find relief with high dose CBD. As
for the risks of cognitive impairment, providers should caution patients that THC can impair
short-term memory which can last several weeks in adolescents and those using higher doses and
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ratios of THC, but ratios with higher CBD can protect against this impairment and improve focus
and concentration.
Efficacy of Cannabis for Various Conditions
The NASEM report concluded there was evidence for the efficacy of cannabis for
treating many medical conditions with various levels of evidence listed below and the type of
cannabis listed in parenthesis when available.
Conclusive and Substantial Evidence Effective For:
•

Chronic pain (cannabis)

•

Antiemetic for chemotherapy-induced nausea and vomiting (oral cannabinoids)

•

Spasticity from MS or spinal cord injury (oral cannabinoids)

Moderate Evidence Effective For:
•

Improving sleep for those with OSA, fibromyalgia, chronic pain, and MS (cannabinoids,
Nabiximols)

Limited Evidence Effective For:
•

Increasing appetite and decreasing weight loss associated with HIV/AIDS

•

Improving clinician-measured MS spasticity symptoms (oral cannabinoids)

•

Tourette Syndrome (THC capsules)

•

Anxiety symptoms for social anxiety disorders (CBD)

•

PTSD (nabilone – THC)

•

TBI + intra-cranial hemorrhage (cannabinoids)

Limited Evidence Ineffective For:
•

Dementia, IOP, and Depression
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Summary for Efficacy of Medical Cannabis
The NASEM report acknowledged the medical utility of cannabis and concluded that it
was safe and effective for many conditions, most notably for treating chronic pain, nausea and
vomiting, spasticity, and sleep disturbances. The report also acknowledged the limitations to
research due to Schedule I status that resulted in ‘insufficient evidence’ at the time to support or
refute the efficacy of cannabis for treating many conditions patients use it for: cancer-associated
anorexia/cachexia, IBS symptoms, epilepsy, spasticity in paralysis due to spinal cord injury, ALS
symptoms, chorea and symptoms from Huntington’s disease, Parkinson’s motor symptoms,
abstinence of addictive substances, schizophrenia (NASEM, 2017). The committee
acknowledged the need for further research and therefore recommended that cannabis be
rescheduled to allow for this (NASEM, 2017).
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CHAPTER 8
THE CURRENT RESEARCH ON MEDICAL CANNABIS
Since the publication of the NASEM report, additional evidence has been collected and
current clinical research has established the efficacy of using cannabis to treat several of the
conditions that the NASEM report found to only have limited or insufficient evidence at the
time, most notably for neurological conditions refractory to conventional treatment: epilepsy,
spasticity, neuropathic pain, insomnia, and addiction (Russo et al., 2018; Sulak, 2021).
Since 2018, clinical trials have been determining the efficacy of cannabis for treating
epilepsy (Phase III - CBD, FDA approved in 2018 as Epidiolex); multiple sclerosis spasticity
(Phase III - Nabiximols, awaiting FDA approval as Sativex in 2021); chronic pain (Phase II THC, Nabiximols), schizophrenia (Phase II - CBD), sleep disturbance (Phase II-III THC,
nabilone, Nabiximols), glaucoma (Phase II - THC), Tourette syndrome (Phase II- THC), and
social anxiety (Phase II- BCD) (Russo et al., 2018). There is also promising clinical research for
the use of medical cannabis with opioid addiction (i.e., CBD during the day and THC at night for
sleep or pain), anxiety and mood disorders (CBD), dementia w/ agitation (low-dose THC),
Parkinson’s Disease (CBD, THC), and PTSD (cannabis) (Sulak, 2021; Russo et al., 2018).
Providers should be aware that the NASEM report provides a comprehensive review of
scientific literature up to 2017 but is outdated now by current research adding to the evidence
daily making it critical to stay abreast of new information and maintain open lines of
communication with patients (TMCI, n.d.).
Resources for Research
The current research for some of the conditions such as anxiety, mood disorders and
schizophrenia were discussed prior while others are briefly summarized below. But more in-
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depth information on all these conditions can be found in the resources mentioned earlier such as
Dr. Sulak’s book and the TMCI and SCC websites. As providers review the research below, it is
important to keep in mind that the most challenging factor for patients using medical cannabis is
figuring out HOW to use it -- what dose, ratio, duration, delivery is most effective for treating
their condition or symptoms. A new software program called CannaKeys was recently developed
to address this need and features up to date meta-analyses of the latest research for nearly 240
conditions and offers insight into clinical dosing summaries and chemotype guidance
(CannaKeys, 2021). Cannabis clinicians that have been working with patients for years are also a
valuable resource that can offer much-needed guidance here. Though much more research is
needed to have evidence-based protocols to properly guide patients, it is important to remember
that some guidance from high quality research and resources is a better alternative to none.
Neuropathic Pain
Chronic pain is the number one reason why patients seek medical cannabis and with
conclusive evidence to support its use (NASEM, 2017). A recent Reuters study analyzing state
registry data that tracks the conditions for which patients use cannabis found 65% of medical
cannabis patients seek cannabis for chronic pain (Rapaport, 2019). A 2021 study offers insight
into which ratios may work best for neuropathic pain, one of the most difficult to treat with
conventional treatment. Using a multicriteria decision analysis, the study compared
pharmacotherapy for chronic neuropathic pain, including cannabis, scoring the drugs on
seventeen effect criteria relative to benefits and safety. The results demonstrated that cannabis
was more effective for chronic neuropathic pain than duloxetine, gabapentin, SSRIs and opioids,
with the most effective ratio being 1:1 THC:CBD (scoring 79 out of 100), followed by CBD-
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dominant (75), then THC dominant (72), with duloxetine and gabapentoids (60’s), amitriptyline,
tramadol and ibuprofen (50’s), morphine and fentanyl (30’s) all less effective (Nutt et al., 2021).
Insomnia
Insomnia is the second most common condition for using medical cannabis and many
patients report improvement in sleep with a variety of chemovars most notably THC-rich
cannabis, but also combinations of THC and CBD-rich, THC and CBN-rich (CBN is known as
cannabinol which can cause drowsiness), and those with terpene content higher in myrcene,
known to be sedating (Kesner & Lovinger, 2020). However, finding the right chemovar and the
right dose is essential to having sedation without the impairment from THC. For example,
research using THC with 1-2 mg CBD found CBD could mitigate the memory-impairing effects
of THC but using CBD doses as small as 5-15 mg was found to interfere with stage 3 sleep
(Nicholson et al., 2004). A recent RCT with 23 patients showed promising results using a
cannabinoid formulation with 10 mg THC/1mg CBD and 0.5 mg CBN, 0.5 mL sublingual
administered one hour to desired sleep time for two weeks. This combination proved to be very
effective for improving sleep and sleep quality and was well-tolerated with the most common
adverse effects being dizziness and dry mouth (Walsh et al., 2021).
Epilepsy
In 2015, a CNN documentary ‘Weed’ publicized the remarkable experience of 7-year-old
Charlotte Figi, who used a whole plant extract high in CBD (1:30, 0.5% THC and 17% CBD)
which reduced her seizures from 40 a day to 2-4 a month (CNN: Weed, 2015). This led many
families desperate for hope to turn to CBD to treat their child’s epilepsy and eventually led to the
development of Epidiolex (Nahler, Jones, & Russo, 2019). Though the NASEM report did not
have enough evidence at the time regarding the efficacy of cannabis to treat seizures, later
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clinical trials using the purified CBD ‘Epidiolex’ revealed it was safe, effective, and in 2018 led
to the FDA-approval in the United States and eventual de-scheduling of all CBD products
(Devinsky et al., 2017; Healthcare professionals [GW], n.d.; Ryan et al., 2021).
A 2018 meta-analysis comparing Epidiolex to whole-plant CBD found whole-plant CBD
had even superior efficacy with approximately 25% of patients using Epidiolex (~27 mg/kg/d)
having over 50% reduction in seizures, while 55% patients using CBD-rich cannabis (~6
mg/kg/d) had over 50% reduction in seizures with lower doses and less side effects (Pamplona et
al., 2018). Other trials using the more effective whole-plant cannabis have found that treating
seizures with cannabis can be very complex, but when proper doses and ratios are found can
profoundly reduce seizures and improve quality of life (QOL), particularly mood, behaviors, and
communication (Rosenbert et al., 2017).
Research has found that CBD-dominant oil works best with a small amount of THC to
reduce excitotoxicity in the brain (1:20-30) and has a wide dosing range (0.05 – 25 mg/kg/d) but
is often effective at lower doses. Trials using CBD-dominant oil found 86% of 272 patients that
had previously failed to respond to anti-epileptic drugs (AEDs) reported benefits, 10% became
seizure-free, 45% reduced seizures by 50%, 14% had no reduction, and 4% had worsening of
seizures (Sulak et al., 2017). This risk is small but should be noted that in the wrong patient and
wrong dose, seizures can increase. Other research using CBD as an adjuvant AEDS found there
were drug-drug interactions (most notably with clobazam where levels were increased by CBD
up to 3-8 times) where levels of AEDs could be raised or lowered depending on which enzymes
they were metabolized by and if CBD inhibited or induced metabolism (Chen et al., 2019;
Devinsky et al., 2018).
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Providers should be aware that CBD can be quite effective at reducing seizures and
improving QOL with no toxicity and much fewer side effects than AEDs when the right dose is
found. However, 4% of patients may see an increase in seizures, and those using CBD in
conjunction with AEDs must be closely monitored for drug interactions. Dr. Sulak’s Healer site
offers helpful information for parents who want to try using CBD to reduce their child’s seizures:
healer.com/pediatric-seizures-video-guide/ (Sulak, 2019).
Opioid Use Disorder
Although no drug is strong enough to solve the tragic opioid epidemic or cure a person
with opioid dependence, cannabis is showing great promise in reducing cravings, use, and harm,
and is a powerful tool that can certainly help (Sulak, 2021). A 2021 report on the impact of
medical and recreation marijuana laws on opioid prescribing found states with cannabis laws
were associated with 9-27% reduction in MME (morphine mg equivalents), decreased
emergency department admissions, and more importantly decreased deaths (Wen et al., 2021)
A 2017 systematic review and meta-analysis revealed that cannabis can prevent opioid
withdrawal, prevent opioid tolerance, and potentiate opioid analgesia leading to reduced doses
(Nielsen, S. et al. 2017). A recent survey on the effect of medical cannabis on prescription
opioids for the treatment of chronic pain found cannabis helped ~40% to stop using opioids,
~43% to reduce dose, with many reporting reduced pain (47%), improved function (80%),
improved QOL (87%) (Takakuwa & Sulak, 2020).
Typical to many conditions using medical cannabis, the challenge is not finding evidence
that cannabis can help but is finding the right dose to increase efficacy and decrease side effects.
A 2015 systematic review on animal studies showed that CBD can reduce the intoxication and
relapse phase through its action at the 5-HT1 receptors where it reduces the reward-facilitating
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effects of morphine but noted that CBD had little effect on withdrawal unless combined with
some THC which was effective at reducing withdrawal symptoms (Prud’homme et al, 2015). A
2019 double-blind RCT with 42 drug-abstinent people with heroin use disorder found that CBD
400 mg and 800 mg were both effective at reducing cue-induced craving and anxiety both in the
short-term (1-2 hours after and 24 hours after taking the CBD) and at 7 days after the final dose
(Hurd et al., 2019). It is noteworthy how quickly CBD worked to reduce cravings and that it
lasted 7 days. It is not likely that levels of CBD in the body were significant 7 days later so the
effects are most likely due to changes in the brain's pathways related to addiction, craving, and
anxiety, demonstrating that the effects of CBD can outlive its presence in the body (Sulak, 2019).
In 2020, a committee of expert cannabis physicians from Canada and the United States
came up with consensus-based recommendations for titrating cannabinoids and tapering opioids
for chronic pain control (See Figure 8.1 below). Their recommendations include starting with 520 mg CBD dominant oral extract, titrating up once or twice weekly as required (with suggestion
to add THC 0.5-3 mg for sleep or with pain, which can also increase by 1-2 mg once or twice
weekly up to 30-40 mg/day) (Sihota et al., 2020).
When the patient reports a minor/major improvement in function, seeks less as-needed
medication to control pain and/or the cannabis dose has been optimized, opioid tapering can be
initiated. The opioid tapering schedule may be 5%-10% of the morphine equivalent dose (MED)
every 1 to 4 weeks (although some clinicians report patients can do a rapid taper in the first two
weeks with 20-50% of MMD) (Sulak, 2021). Clinical success is defined by an improvement in
function/quality of life, a ≥30% reduction in pain intensity, a ≥25% reduction in opioid dose, a
reduction in opioid dose to <90 mg MED and/or reduction in opioid-related adverse events
(Sihota et al., 2020).
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Figure 8.1 Consensus-based recommendations for tapering opioids. Image from International
Journal of Clinical Practice 75(8), used with permission from Wiley.com.

Hepatitis C
Many patients with Hepatitis C use cannabis to help with nausea and pain and to endure
the side effects from Hepatitis C medications, and research found that those using cannabis
concurrently with Hepatitis C IV meds were more likely to complete and respond to treatment.
However, the ECS can modulate liver fibrogenesis with bidirectional effects, with CB1
activation promoting fibrosis and CB2 activation inhibiting it, and warrants caution, especially
when using THC. A 2008 study on patients with Hepatitis C using high doses of THC was
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associated with increased fibrosis in patients with active inflammation and scarring already
present (Ishida et al., 2008). However, a later study in 2014 found patients with hepatitis C
without active inflammation and scarring had no evidence of increased fibrosis with use of
cannabis (Liu et al., 2014).
Research on use of CBD for patients with Hepatitis C shows the potential for CBD to
prevent liver scarring and inflammation in hepatitis C (Lim et al., 2011). Preclinical evidence
using CBD to treat chronic liver disease shows CBD can reduce steatosis and fibrosis in liver by:
reducing lipid accumulation, stimulating autophagy, modulating inflammation, reducing
oxidative stress, and inducing death of activated hepatite stellate cells (DeTernay et al.,
2019). Providers need to be aware of the potential for high dose THC in those with active
inflammation and scarring to increase fibrosis, but also of the potential for CBD to prevent and
reduce liver inflammation and scarring, and to advise patients to use CBD-rich cannabis
accordingly.
Other Neurological Disorders
Recent research highlights the safety and efficacy of using THC, CBD, THCA, CBDA in
the treatment of many neurological disorders refractory to conventional treatment such as
intractable epilepsy, brain tumors, traumatic brain injury (TBI), Parkinson’s Disease (PD), and
Alzheimer’s Disease (AD) and warrants further clinical research (Russo et al., 2018). A 2020
study reported on novel therapeutic approaches to PD and AD that involve modulating the ECS
by using FAAH/MAGL inhibitors which prevent breakdown of endocannabinoids and increase
levels indirectly. The study found this led to a “reduction in amyloid β-protein deposition and
inhibition of the death of dopamine neurons, which are commonly accepted to underlie the
pathogenesis of AD and PD, respectively” (Ren et al., 2020).
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Other studies on PD show the potential of cannabis to improve symptoms but difficulty in
determining which chemovar or cannabinoids are most effective. For example: 49.5% of 339
patients with PD using oral cannabis leaves (CBDA,THCA) for three months improved general
function, resting tremor, bradykinesia, and rigidity with few side effects; an open-label
observational study of 22 patients with PD smoking cannabis (THC-rich) reported significant
improvement in tremor, rigidity, bradykinesia, and also in sleep and pain, with few side effects;
and a case series with four pts with PD and REM sleep behavior disorder had prompt and
substantial reduction in the frequency of RBD-related events using 75 mg of CBD for 3 pts and
300 mg for one patient (Chagas et al., 2014; Lotan et al., 2014; Venderová et al., 2004).
Research on AD has found that low dose THC can be effective at improving symptoms:
39 pts with agitation in moderate to severe AD using Nabilone (THC) for 14 weeks showed
significant reduction in agitation over 6 weeks and greater clinical improvements than similar
RCTs using antipsychotics and antidepressants; an open-label pilot study in Israel on 11 patients
with AD used 2.5-7.5 mg of THC twice a day and found significant reduction in delusions,
agitation, aggression, apathy, sleep and caregiver distress; and a prospective observational study
on 10 patients with severe dementia using low dose 1:2 THC/CBD, ~8 mg/16mg per day
divided three times a day for two months greatly improved behavior problems, rigidity, and daily
care, with some able to stop or decrease their opioids, benzodiazepines, and antipsychotics
(Herrmann et al., 2019; Shelef et al., 2016; Broers et al., 2019).
Research on using cannabis to help with TBI is just as promising. A systematic review
and meta-analysis on using CBD in experimental stroke showed CBD at time of injury reduced
size of brain lesion an average of 20% and reduced early and late impairment (England et al.,
2015). A study on preclinical and clinical models for neurodegenerative disorders and
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stroke/brain trauma showed CBD 1mg/kg improved vascular supply, reduced inflammation,
promoted neurogenesis (Fernández-Ruiz et al., 2015). A preclinical study on mice found shortterm CBD 10 mg/kg can reduce neuroinflammation and promote neuroplasticity and functional
recovery after brain ischemia reporting that CBD: prevented the cognitive/emotional impairment,
attenuated hippocampal neurodegeneration and white matter (WM) injury, and reduced glial
response that were induced by bilateral common carotid artery occlusion (BCCAO); in ischemic
mice, exhibited an increase in the hippocampal BDNF brain derived neurotrophic factor (BDNF)
protein levels; and stimulated neurogenesis and promoted dendritic restructuring in the
hippocampus of BCCAO in mice (Mori et al., 2017). Another recent study using piglet models of
newborn hypoxic-ischemic brain damage found CBD reduced death of neurons, preserved brain
activity, prevented seizures, improved neurobehavioral performance at 72 hours and 30 days
after injury, and had synergistic effects with hypothermic treatment (Barata et al., 2019).
Cancer
There is conclusive evidence that medical cannabis is safe and effective for reducing
symptoms caused by chemotherapy such as nausea, vomiting, anorexia, chronic pain, and
insomnia (NASEM, 2017). Many doctors find it safer to use cannabis for these symptoms than
writing multiple different prescriptions that may interact with each other or cancer-directed
treatment (Abrams et al., 2015).
However, there needs to be caution with claims that cannabis can kill cancer as not
enough research proves or recommends this in lieu of conventional treatment. Though cannabis
may show potential to kill cancer due to its anti-neoplastic properties, cancer is incredibly
complex and so is cannabis with its hundreds of different compounds. There are some preclinical
studies that show THC and CBD combined demonstrate anti-cancer properties -- triggering
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apoptosis, preventing cell growth and division, preventing angiogenesis, preventing metastasis.
(Ladin et al, 2016; López-Valero et al., 2018). There are reports of objective clinical responses in
119 cancer patients given pharmaceutical CBD 10-30 mg twice daily in bursts, three days on and
three days off with clinical response in 92% of the cases, but the responses only emerged after
six months of treatment (Kenyon et al., 2018). There is also evidence that cannabis may have
potential as an adjunct to treatment. A phase II RCT in 21 patients with recurrent glioblastoma
used Nabiximols added as adjunct to Temozolomide showing the one-year survival rate was 83%
w/ Nabiximols and 56% w/ placebo, with median survival >550 days with Nabiximols versus
369 days with placebo (Twelves et al., 2017).
However, much more research is needed before recommending cannabis to kill cancer,
and there are also some cautions for using medical cannabis as an adjunct with immunotherapy.
For example, studies using cannabis as an adjunct with Nivolumab show the immunomodulatory
effects of cannabis may inhibit effectiveness of cancer immunotherapy (Bar-Sela et al., 2020;
Taha et al., 2019). Cannabis clinicians advise patients using immunotherapy who also want to
use cannabis to treat symptoms to use only low doses and to skip dosing two days before and
five days after injection (Sulak, 2021).
As well, pre-clinical research from Israel demonstrates the complexity of trying to use
cannabis to treat cancer and how various compounds in cannabis other than THC and CBD may
play a larger role than previously thought. The study used cannabis strains that had similar
amounts of THC and CBD but different levels of THCA, CBDA, and CBG. The results found
that one strain killed colon cancer cells but had no impact on prostate cancer cells, while another
strain killed prostate cancer cells but had no impact on colon cancer cells, revealing that the
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minor cannabinoids may be a critical factor in determining how to use cannabis to kill different
types of cancer and that further research on these is urgently needed (Baram et al., 2019).
Providers need to be aware that there is conclusive evidence that cannabis is safe and
effective for reducing symptoms from chemotherapy and improving quality of life. However,
caution needs to be used with immunotherapy and more research is needed before
recommending cannabis as an anti-cancer treatment as the effects vary significantly based on the
type of cancer and cannabis preparation.
Summary of Current Research
In summary, there is existing and emerging research that demonstrates medical cannabis
can have a therapeutic role for improving many conditions patients suffer from in clinical
practice such as chronic pain, neuropathic pain, insomnia, inflammation, spasticity, intractable
seizures, nausea and vomiting, anxiety, depression, addiction and opioid use disorder, and
several neurological disorders refractory to conventional treatment. Cannabis contains over 500
pharmacological and biochemical compounds, of which only a few are understood, so there are
likely more potential therapeutic uses that remain undiscovered. More research needs to be done,
especially regarding most effective doses and ratios, but there is enough quality evidence to
know that medical cannabis is safe and effective and can help many, especially those with
conditions refractory to conventional treatment. Providers need to be educated on the benefits,
risks, and pharmacology of medical cannabis to realize it can be a powerful tool for providers
and patients to use to help many find relief from suffering and improved quality of life
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CHAPTER 9
THESIS RESEARCH
Methodology
This research involves a one-hour presentation on medical cannabis given to medical
providers in Maine via live and pre-recorded sessions including a PowerPoint and pre/post
survey.
The presentation includes a 50-minute PowerPoint titled “The Medical Use of Cannabis
in Clinical Practice” which consists of condensed highlights mostly from the Healer Medical
Cannabis Training and Certification program designed by internationally acclaimed cannabis
specialist Dr. Dustin Sulak, used with permission. It also contains elements of “The Medical Use
of Cannabis” course from The Medical Cannabis Institute which offers accredited online medical
cannabis education for healthcare professionals and state-specific certification, developed in
collaboration with the Society of Cannabis Clinicians, a group of expert cannabis physicians and
scientists, of which Dr. Sulak is also a board member.
The PowerPoint will be narrated in person for the live sessions and by audio recording
for the pre-recorded sessions. For those requesting a pre-recorded presentation, the PowerPoint
with audio recording and consent/survey packets will be emailed to a clinical coordinator who
will forward this information to the providers and medical students.
The presentation also includes a 5-minute anonymous paper survey to be completed
immediately prior to and post presentation. The survey consists of Likert-scale questions to
gather feedback on providers’ knowledge of medical cannabis and comfort level guiding patients
who use it, possible barriers to discussing/recommending medical cannabis with patients, and the
impact of the presentation on these barriers (See APPENDIX A: PRE/POST SURVEY). The
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survey questions on barriers come from the same survey given to Minnesota oncologists to
assess barriers (Zylla et al., 2018) and were used with permission from the study’s leading
author, Dylan Zylla.
A consent form will be attached to the front of the paper survey (See APPENDIX B:
CONSENT FORM). For the live sessions, this packet with the consent and survey will be
distributed immediately prior to presentation and collected immediately post presentation by
principal investigator. For pre-recorded sessions, the principal investigator will mail the consent
and survey packets to the clinical coordinator who will distribute these packets immediately prior
to the participants receiving the pre-recorded sessions and collect them after the session is
viewed.
The participants targeted are medical providers who are at least 18 years old and work
with patients in clinical practice at all levels (i.e. MD, DO, NP, PA, RN, and RN students). All
levels of providers are included, student nurses as well, to maximize participation as well as to
gather a wider array of possible barriers to providers discussing cannabis. For example, the
concern of legal ramifications or stigma might be more relevant to some levels of providers than
others and might therefore benefit from a more targeted intervention at that level. The level of
degree, years of practice, and area of practice are the only demographic information that will be
gathered on the survey to delineate these differences. Since the presentations are voluntary with
no compensation or CME credit, the number of participants is projected to be small, with the
total expected number from all sessions being 25-50.
Results
There were 24 total participants with six total participants returning their survey -- a
response rate of 25%. The results of the survey are below with the percentage of change from
pre- to post-survey noted in the right column.
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Table. 10.1 Results from pre/post survey.
I am familiar with the endocannabinoid system and how it works.
I am aware that cannabis has ~530 different compounds (120 different
cannabinoids) in cannabis that each have different pharmacologic effects.
I am aware there are different preparations of cannabis (i.e. chemovar,
strains) that vary in their percentage of these compounds most notably
their ratio of the two major cannabinoids THC:CBD
I am familiar with which ratios (i.e., higher in THC or CBD, or 1:1) are
most effective for these common qualifying conditions:
Chronic Pain/Neuropathies
Insomnia
Nausea/Vomiting/Cachexia
Anxiety/ Depression
Epilepsy/Seizures
Multiple Sclerosis/Spasms
Addiction/Opioid Reduction and Cessation
I am aware of the benefits of the major cannabinoids.
I am aware of the risks of the major cannabinoids.
I am aware of the potential adverse effects + drug-drug interactions.
I am aware of best practices to maximize benefit and minimize harm with
medical cannabis use (i.e., ratio/product selection, no smoking, lowest
dose, slow titration prn, avoiding tolerance by resensitizing receptors)
I feel comfortable discussing the risks and benefits of medical cannabis
with patients.
I am likely to discuss the use of medical cannabis with patients who
struggle with the conditions above known to benefit from use.
Possible barriers to me discussing medical cannabis with patients are:
Products are not FDA approved
Unsure about risks/benefits
Inadequate research to justify use
Concern about abuse/misuse
Concern about quality/consistency of product
Unsure about legal ramifications to me
Unsure about legal ramifications to patient
Concern about cost to patient
I don’t want to be identified as one who supports cannabis use

I am interested in learning more about medical cannabis.
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83% improvement
100% improvement
100% improvement

83% showed improvement in all
conditions ranking their familiarity
at moderate+,
17% showed no change

100% improvement; 83% “veryextremely aware”
83% improvement; 100% “very to
extremely aware”
83% improvement; 100%
“moderately to extremely aware”
100% improvement

67% improvement; 100%
“moderately to extremely
comfortable”
67% improvement; 100%
“moderately to extremely likely”
17% NO RESPONSE ON PRESURVEY
60% improvement; Tied for #2
ranking
80% improvement
60% improvement; Tied for #2
ranking
60% improvement
60% improvement; #1 ranked
barrier
100% improvement
100% improvement
80% improvement; Tied for #2
ranking
60% improvement
33% improvement; 100%
“moderately to extremely
interested”

Discussion
Limitations of Study
The results were limited by the small sample size, low response rate of 25%, and the lack
of diversity with five of the six surveys coming from the live presentation at Northern Maine
Medical Center (NMMC) and one survey coming from the providers at University of Maine
Cutler Health Center in Orono who watched a PowerPoint recording of the presentation. This
low response rate and lack of diversity was unanticipated and due to poor timing. The
presentation was unfortunately delayed and had to be offered during the last week of summer
when most providers at Cutler Health were trying to use their summer vacation time before
classes started which led to only one provider electing to participate. Perhaps if there were more
incentive to watch the presentation like CME credits, more would have participated.
NMMC did have more participants but was still small with twenty-three attending out of
sixty who were sent the flyer. As well, the majority elected to participate via zoom due to an
unanticipated COVID outbreak that shut down three nearby school systems to ‘remote learning
status’ the same day the survey and presentation were being administered. The clinical
coordinator had sent an email prior to the presentation with an attached survey, consent form,
and reference packet. But only one provider printed the survey out, competed it, and returned it
to the clinical coordinator. The clinical coordinator and principal investigator attempted to
contact the providers via email as well as in person, but many were not on site or at work due to
being off or working the nightshift, and some worked in satellite locations or were medical
students unable to be reached.
In hindsight, the fact that the survey was not electronic seemed to be a large hinderance
to busy providers returning the survey. In future studies, especially considering the current

60

COVID pandemic shifting the workplace to remote, the survey should be electronic, possibly
through Qualtrex, to allow for remote participation and ease of survey completion on-line.
The results were also limited by the length of the presentation as some providers from
Northern Maine Medical Center had to rush back to their patients waiting for them to return from
Grand Rounds. One provider repeatedly interrupted the presentation with objections to the topic
and questions, some on content just covered, which made it difficult to get through the whole
presentation. This provider revealed after the presentation that he wanted more time to be built in
for questions and discussion. Some questions were addressed before, during, and after the
presentation as time allowed and in follow-up emails from the author. But these responses were
only seen by the providers asking the questions, so other providers did not benefit from the
seeing the response. As well, there were some excellent questions on pharmacodynamics that
were addressed in the presentation but perhaps too quickly and might have been better processed
and understood with more time to process and pause for questions. In hindsight, the presentation
might have had more of an impact if it was broken into two smaller 30-minute presentations with
more time intentionally built in for questions before, during, and after and for follow-up
discussion.
The other limitation is due to possible confirmation bias from the principal investigator
who admittedly had a personal conflict of interest due to her son using medical cannabis to stop
his seizures since age nine. Attempts to mitigate this bias, to avoid looking for results that
confirmed the presentation was successful, were made by ensuring the analysis of the results
were strictly by the numbers and percentages. However, the bias is still possible and needs to be
considered.
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Implications of Research
Despite these limitations, the results that were collected did show statistical evidence of
the educational intervention being successful at addressing the barriers to providers discussing
medical cannabis with their patients. There was also evidence that the presentation had a
significant impact on both the providers’ comfort level and likelihood of them guiding their
patients use of medical cannabis in the future. This change is most critical to improving patient
care with medical cannabis as some guidance is better than none and patients left on their own.
The percentage of providers that improved their comfort level with discussing cannabis
was 67%, with 33 % staying at the same comfort level as “moderately comfortable”. This change
may seem modest until comparing it with the levels of comfort pre-presentation where 50% of
providers reported being “not at all to slightly comfortable discussing cannabis” to postpresentation where 100% of providers reported being “moderately to extremely comfortable
discussing cannabis”. This change in mindset, being open to an idea that one was closed off to
prior, is often the hardest to change and has the most long-standing ripple effects. Any growth
here is significant.
The providers’ willingness to engage in discussions with their patients also increased
after the presentation. In fact, pre-presentation results revealed 67% of providers said the
likelihood of them discussing medical cannabis with patients was “not at all or slightly likely”.
However, post-presentation showed 83% of providers said they would be “moderately to
extremely likely” to discuss medical cannabis with their patients, a significant improvement.
This improvement in providers’ willingness to guide their patients will also have a significant
impact on patients, many of whom are currently on their own experimenting to find their right
dose and ratio and are desperate for some guidance from medical providers.
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The increase in providers’ confidence with and likelihood of discussing medical cannabis
with their patients is correlated with a significant increase in their level of knowledge regarding
medical cannabis. Post-presentation, 100% of providers reported an increase in their awareness
of cannabis pharmacology, cannabis preparation, best practices to mitigate harm and maximize
benefit, with 67% going from “not at all or slightly aware” to “moderately to extremely aware”.
As well, 83% of providers reported an increase in their level of awareness of the
endocannabinoid system and familiarity with which ratios are most effective for the most
common qualifying conditions. Since one of these conditions is opioid use disorder which is
causing significant harm to patients and society, this change could have deep and wide-ranging
benefits for patients and society.
Providers’ awareness of risks and benefits of medical cannabis use also increased
significantly. Post-presentation, 100% of providers reported an increase in their awareness of the
benefits of medical cannabis with 100% reporting they were now “moderately to extremely
aware”. This is a significant change from pre-presentation where 50% of providers reported they
were “not at all to slightly aware” of the benefits. The awareness of the risks and potential
adverse effects also increased post-presentation with 83% of providers reported they were “very
to extremely aware” of the risks compared to pre-presentation where 50% providers reported
they were “not at all to slightly aware”. Since the requirement for medical certification in Maine
is for a provider to deem a patient may benefit from use of cannabis and ensure that they
discussed the risks and benefits of use, this improvement can also increase the number of future
patients receiving medical certification.
The questions on barriers had mixed results sometimes contradicting the participants
reported level of increased knowledge and comfort level. This is perhaps due to the phrasing of
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the questions and their placement at the end of the survey, as some participants circled the whole
row the same, seemingly in a rush, and one did not complete it at all.
However, there are some findings regarding perceived barriers that could highlight a need
for further interventions. For example, the barrier that was most often listed for providers
discussing cannabis both pre- and post-presentation was their “concern about quality/consistency
of products”. This concern largely exists due to the current status of cannabis being federally
illegal which prevents federal oversight for products and more pharmaceutical-grade cannabis
preparations. Until cannabis is rescheduled, it might help to do a follow up presentation for
providers explaining how and where patients can find safe, effective products in Maine that are
tested in a third-party laboratory and perhaps listing the places to find rankings of the top
companies on-line with the highest quality products.
The other three barriers that providers ranked highly were also directly related to the
status of cannabis being Schedule I: inadequate research, products not being FDA approved, and
cost to patient. All three of these barriers could be addressed by cannabis no longer being
federally illegal, a status that significantly hinders research, access to quality medicine, and
prevents the cost being covered from insurance. These barriers highlight the need for providers
to advocate for legislation that proposes rescheduling cannabis, such as the recently proposed
“Cannabis Administration and Opportunity Act” advocating to remove all cannabis from
scheduling to allow regulation and tax (Fandos, 2021). It is estimated that 70% of the American
public now support the legalization of cannabis, so if providers could also express their support
and advocate for rescheduling, it may be the push needed for legislation to finally pass (Fandos,
2021). The American Association of Nurse Practitioners has a site specifically designated for
this purpose called ‘Advocacy Center’ that helps providers easily contact legislators and make

64

their voices heard on recent legislation, which can be accessed here:
https://www.aanp.org/advocacy/advocacy-center.
Meanwhile, until cannabis is rescheduled, these barriers do exist and need to be actively
countered. For example, one provider in Maine shared their concern about ‘gag orders’, both
written and unwritten, where hospitals actively tell providers not to discuss cannabis, saying if
they did so, they would lose federal funds due to being a rural health center. The principal
investigator attempted to find evidence of this ‘gag order’ in the by-laws or any evidence that
showed federal funds ever being withheld. But no evidence was able to be found for either of
these by the time of this writing. However, this barrier to discussing and recommending medical
cannabis was specifically addressed in the presentation by sharing a slide reviewing the 2000
court case that ruled this speech was protected by the first amendment ‘freedom of speech’ and
the 2002 court case confirming this ruling and stating that any move by the government to
penalize or investigate a provider for discussing or recommending cannabis was strictly
prohibited (Conant vs McCaffrey, 2000; Conant HIV AIDS vs Walters DEA, 2002). Hopefully,
with more education on these court rulings, more providers will be aware of their rights to
discuss and recommend cannabis and will start actively speaking out against written or unwritten
policies trying to intimidate or silence their rights.
Many perceived barriers could also be addressed by future educational presentations, for
example “Best practices for guiding patients to find safe and cost-effective medicine”, and
“Exploring cannabis educational resources for the most current, high-quality research and
evidence-based guidelines”. The results of the surveys made the author more aware of the extent
to which most providers lacked knowledge on medical cannabis, with many lacking knowledge
on even simple basic understandings of the endocannabinoid system and pharmacodynamics of
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the two major cannabinoids that are critical to understanding how medical cannabis works. In
hindsight, the providers needed more time to process the information and to ask questions to
cement their new understanding of the material presented. Future presentations that break up the
delivery into smaller 30-minute presentations that allow more time for questions, processing, and
discussions, may have an even greater impact.
Conclusion
In summary, millions of patients are using medical cannabis and in need of guidance
from their providers, most of whom lack the necessary knowledge and confidence to guide their
patients’ use of medical cannabis. However, brief educational presentations for providers on
medical cannabis can successfully increase providers’ knowledge on the risks and benefits of
medical cannabis. It can also increase providers’ confidence with and likelihood of discussing
medical cannabis use with patients. The significance of the results from the educational
intervention used here is limited by the small sample size and number of surveys returned, but
the overall positive results offer hope for future educational interventions and more patients
having guidance from their providers in the future. In fact, 100% of the providers surveyed postpresentation reported they were “moderately to extremely interested” in learning more about
medical cannabis. This research has inspired the author to do more presentations on medical
cannabis in the future for providers, of shorter duration to allow for questions, both in person and
on-line to make it more accessible to providers. Hopefully, future education for providers will
result in less patients having to suffer needlessly or having to experiment on their own to find
medicine to help them heal with less harm and improved quality of life.
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APPENDIX A: PRE/POST SURVEY
Degree/s: _______ Years of Practice: ______ Area/s of Practice: _______________________
Please rate the following statements pre and post presentation, from 1-5.
(1 = Not at all, 2 = Slightly, 3 = Moderately, 4 = Very, 5 = Extremely)
PRE

POST

I am familiar with the endocannabinoid system and how it works.

1 2 3 4 5

1 2 3 4 5

I am aware that cannabis has over 530 different compounds (120 different
cannabinoids) that each have different pharmacologic effects.

1 2 3 4 5

1 2 3 4 5

I am aware there are different preparations of cannabis (chemovar/strains)
that vary in their percentage of these compounds, most notably their ratio
of the two major cannabinoids THC:CBD

1 2 3 4 5

1 2 3 4 5

I am familiar with which ratios (i.e., THC-rich, CBD-rich, 1:1 equal ratio)
are most effective for the common qualifying conditions:
Chronic Pain/Neuropathies
Insomnia
Nausea/Vomiting
Anxiety/ Depression
Epilepsy/Seizures
Multiple Sclerosis/Spasms
Addiction/Opioid Reduction and Cessation

1
1
1
1
1
1
1

1
1
1
1
1
1
1

I am aware of the benefits of the major cannabinoids.

1 2 3 4 5

1 2 3 4 5

I am aware of the risks of the major cannabinoids.

1 2 3 4 5

1 2 3 4 5

I am aware of the potential adverse effects of cannabis use.

1 2 3 4 5

1 2 3 4 5

I am aware of best practices to maximize benefit + minimize harm with
medical cannabis (i.e., ratio/product selection, no smoking, lowest dose,
slow titration, avoiding tolerance by resensitizing receptors)

1 2 3 4 5

1 2 3 4 5

I feel comfortable discussing the risks and benefits of medical cannabis
with patients.

1 2 3 4 5

1 2 3 4 5

I am likely to discuss the use of medical cannabis with patients who
struggle with conditions known to benefit from use.

1 2 3 4 5

1 2 3 4 5
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2
2
2
2
2
2
2

3
3
3
3
3
3
3

4
4
4
4
4
4
4

5
5
5
5
5
5
5

2
2
2
2
2
2
2

3
3
3
3
3
3
3

4
4
4
4
4
4
4

5
5
5
5
5
5
5

Possible barriers to me discussing medical cannabis use with patients are:
Products are not FDA approved
Unsure about risks/benefits
Inadequate research to justify use
Concern about misuse/abuse
Concern about quality/consistency of product
Unsure about legal ramifications to me
Unsure about legal ramifications to patient
Concern about cost to patient
I don’t want to be identified as one who supports cannabis use

1
1
1
1
1
1
1
1
1

I am interested in learning more about medical cannabis.

1 2 3 4 5
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2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4

5
5
5
5
5
5
5
5
5

1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4

5
5
5
5
5
5
5
5
5

1 2 3 4 5

APPENDIX B: CONSENT FORM
CONSENT FORM FOR ANONYMOUS SURVEY
You are invited to participate in a research project being conducted by Arianne Kryskow a
graduate student in the Family Nurse Practitioner program at the University of Maine School of
Nursing with assistance from Dr. Patricia Poirier, Professor of Nursing. The purpose of the
research is to assess the need for and benefit of medical cannabis education for medical
providers. You must be at least 18 years of age to participate.
What Will You Be Asked to Do?
If you decide to participate, you will be asked to view a 45-minute educational PowerPoint and
to complete an anonymous 5-minute survey immediately prior to and following the PowerPoint,
total time estimated at 1 hour. The survey will ask you to rate statements such as “I am aware of
the risks and benefits of the major cannabinoids” and “I am aware of the contraindications for
medical cannabis use” on a Likert-type scale of 1-5 with 1 being “Not at all” and 5 being
“Extremely”. For those viewing the presentation live, you will return the survey immediately
after the presentation to Arianne Kryskow. For those viewing prerecorded sessions, please return
the survey immediately after viewing recording to Mr. Sean Sibley.
Risks
Except for your time and inconvenience, there are no risks to you from participating in this
study.
Benefits
This presentation will increase your knowledge of medical cannabis use (i.e. current research on
the clinical utility, risks and benefits, contraindications, strategies to maximize benefit and
minimize harm) and your comfort level with guiding patients who use medical cannabis.
This study will also help inform the need for and benefit of future medical cannabis education for
medical providers.
Confidentiality
This study is anonymous. Please do not write your name on the survey. There will be no
records linking you to the data. Surveys will be stored in a locked drawer and the data
aggregated in a password-protected computer. All data will be destroyed by December 20, 2021.
Voluntary
Participation is voluntary. If you choose to take part in this study, you may stop at any
time. You may skip any questions you do not wish to answer. Submission of the survey implies
consent to participate.
Contact Information
If you have any questions about this study, please contact Arianne Kryskow at 207-436-0483 or
arikryskow@gmail.com You may also reach the faculty advisor on this study at
patricia.poirier@maine.edu. If you have any questions about your rights as a research participant,
please contact the Office of Research Compliance, University of Maine, 207-581-2657 (or e-mail
umric@maine.edu).
84

APPENDIX C: CERTIFICATE OF ANALYSIS (COA). Edited Sample.

85

86

BIOGRAPHY OF THE AUTHOR
Arianne Kryskow lives in Fort Kent, Maine with her husband and two children. She has
over twenty years of experience as an English teacher and guidance counselor in Maine and
loved helping children and families. However, after witnessing how medical cannabis stopped
her son’s seizures completely, Arianne recently switched her career to the medical field to help
other families access cannabis. She attended the University of Maine in Fort Kent to receive her
Accelerated Nursing Degree in the summer of 2018 and entered the Family Nursing Practitioner
program at The University of Maine in Orono in the fall 2018. Arianne aspires to work in an
integrative health clinic where she can help people find healing and quality of life on their own
terms. Arianne is a candidate for the Master of Science degree in Nursing from the University of
Maine in December 2021.

87

